



Cite this: *Chem. Soc. Rev.*, 2022, **51**, 2081

Received 29th September 2021

DOI: 10.1039/d1cs00798j

rsc.li/chem-soc-rev

Peptide probes for proteases – innovations and applications for monitoring proteolytic activity

Maria Rodriguez-Rios, ^a Alicia Megia-Fernandez, ^a Daniel J. Norman ^b and Mark Bradley ^{*a}

Proteases are excellent biomarkers for a variety of diseases, offer multiple opportunities for diagnostic applications and are valuable targets for therapy. From a chemistry-based perspective this review discusses and critiques the most recent advances in the field of substrate-based probes for the detection and analysis of proteolytic activity both *in vitro* and *in vivo*.

Introduction

Proteases are enzymes with wide-ranging and crucial activities that mediate the hydrolysis of amide bonds. The residues within the active site of the enzyme responsible for the biological activity allow the partitioning of these enzymes into the five major classes: so-called serine, threonine, cysteine, aspartic acid or metallo-based proteases. Cleavage by proteases typically occurs on well-defined substrates to allow for discrete and precise regulation of biological functions and takes place

between two amino acids (P1–P1') (by endopeptidases) or at the N- or C-terminus of the peptide (by exopeptidases). Proteases need to recognise their substrate to allow exertion of its function, with the most crucial amino acid being that located on the P1 position of the scissile bond. The degree of substrate specificity is variable, with some proteases accepting a broad spectrum of substrates and others accepting very few.

The function of proteases is essential for an abundance of cellular processes, that includes matrix remodelling by metalloproteinases during cell growth, angiogenesis and tissue remodelling;¹ regulation of cell division by the calpain family² and the control of programmed cell death by caspases.³ These physiological proteolytic functions are tightly

^a EaStCHEM School of Chemistry, University of Edinburgh, David Brewster Road, EH9 3FJ Edinburgh, UK. E-mail: Mark.Bradley@ed.ac.uk

^b Technical University of Munich, Tropfstrasse, 30, 81675, Munich, Germany



Maria R. Rios

of fluorogenic peptide-based probes for imaging inflammation.

Maria Rodriguez-Rios received her bachelor's degree in Biochemistry from the Universitat Autònoma de Barcelona in 2015. She obtained a MSc in Drug Design and Biomedical Sciences from Edinburgh Napier University, working on the development of optical probes for cancer imaging. Following a short period working in industry, she started her PhD studies at the University of Edinburgh under the supervision of Professor Mark Bradley working on the synthesis



Alicia Megia-Fernandez

appointed to a Maria Zambrano Senior Fellowship at the University of Granada. Her current research interests are in Chemical Biology and include chemical methodology and molecular imaging probes for diagnosis and treatment of different diseases.

Alicia Megia-Fernandez, MRSC, obtained her MSc degree in Chemistry and PhD from the University of Granada, Spain, under the guidance of Professor Santoyo-Gonzalez, where she was awarded the Extraordinary PhD Award in Experimental Science. This was followed by the award of Fundación Ramón Areces and Marie Curie IEF Fellowships to work as a postdoctoral researcher at the University of Edinburgh with Professor Bradley. In 2022 she was



regulated and dysfunction of proteases can be highly detrimental and has been linked to a variety of diseases with examples including cancer,⁴ diabetes,⁵ inflammation,⁶ vascular diseases⁷ and Alzheimer's.⁸ Indeed, Alzheimer's disease, which is characterised by a cognitive decline, is associated with an accumulation of amyloid- β (A β) plaques produced by a sequence of proteolytic events of the amyloid precursor protein by α -, β - and γ -secretases that result in aggregation and generation of A β .⁸ The disease-causing proteolytic network of Alzheimer's disease exemplifies the need for specific and versatile protease probes in order to distinguish and elucidate the biochemical processes responsible, such as chemical probes that enable the specific identification of the aspartyl protease γ -secretase.⁹ Proteases have emerged as excellent disease biomarkers. For instance, thrombin is widely used as a biomarker in the diagnosis of blood disorders and prostate cancer. Proteases are also attractive drug targets, with a variety of inhibitors developed used to treat diseases such as the HIV-1 protease inhibitors to treat AIDS,¹⁰ and captopril to treat hypertension.¹¹

Understanding the role of proteases in disease and the evaluation of treatment efficacy are crucial for the success of the drug development process, but current gold-standard methods typically rely on *in vitro* detection by genetic expression measurements or immunostaining. However, these methods base their detection on indirect measurement of protease concentration instead of proteolytic activity and they cannot distinguish between active and inactive (pro-forms) of the protease. Peptide-based probes have emerged as an alternative to these methods to allow the evaluation of the activity of a variety of proteases.^{12,13} A key advantage is that these probes rely solely on "real" proteolytic activity and allow both *in vitro* and *in vivo* evaluation in real time. These probes typically contain a peptide-targeting moiety (that is recognised by the protease) and a reporter (*e.g.* a fluorophore, a contrast agent, an electrochemical tag or a mass tag). Peptides are ideal as the

recognition element as they mimic the endogenous substrate and offer high natural specificity, while providing a scaffold for the attachment of labels or signal transducers.

In vivo imaging of proteolytic activity is becoming extremely useful in the area of diagnostics or for optical-image-guided surgery.¹⁴ Fluorescent peptide-based probes are widely used in optical imaging, with many efforts pushing into the near infrared imaging window of the spectrum,¹⁵ where biological tissues are silent and penetration of light is enhanced. In recent years, other approaches have made an appearance as promising alternatives to fluorescence-based technologies. These include chemiluminescent probes, that do not need an external light source and provide virtually no background signal, and photo-acoustic imaging that offers great promise for deep-tissue imaging, with the main advantage of being able to image tissue at depths of more than 1 cm.

Bench-top or *in vitro* technologies for laboratory analysis of proteolytic activity have seen advances in the area of colorimetric detection; with applications for *in vitro*, low cost and easy-to-read analysis, electrochemical probes, with redox-based detection of proteases offering an alternative to other methods where complex media samples might affect other detection methods such as fluorescence. The area of MS and proteomics has seen proteolytic profiling appearing with applications in disease diagnostics and comparative analysis of proteolytic activity in health and disease. In this review, we discuss recent advances in the area of probes for the detection of proteases and new strategies in the area of FRET, pro-fluorophores, bioorthogonal reactions, aggregation-induced emission and chemiluminescence based optical probes as well as methods based on photoacoustic contrast agents, electrochemical detection, mass spectrometry and colorimetric reporters.

Comprehensive reviews have been published in the field of protease activity and we would like to highlight those of Ong,¹⁶ Oliveira-Silva¹⁷ and Zhang.¹⁴



Daniel J. Norman

tuberculosis, he began a post-doc position at the Technical University of Munich with Dr Hannelore Meyer in drug discovery of novel antibiotics and β -lactamase inhibitors for resistant infections.

Dr Daniel Norman obtained his BSc (Hons) at the University of Dundee in Medicinal Chemistry and then worked on the development of peptide-based hydrogels at Biogelx. He obtained his PhD in Chemistry at the University of Edinburgh under the guidance of Prof. Mark Bradley with a research focus on novel prodrug activation methods for cancer treatment. Following a post-doctorate with Professor Bradley developing diagnostics for



Mark Bradley

*Professor Mark Bradley has led research groups in the UK for over 30 years with funding from across the research councils and a variety of commercial and translational concerns. He has published over 440 papers and book chapters, has an H-factor of 62, filed >25 patents and spun-out five (still active) companies. The main focus of the Bradley group is in the area of life-sciences, specifically the application of the tools of chemistry to allow the manipulation, control and understanding of specific biological processes and functions and to address specific biological questions, problems in the areas of fluorescent reporters, smart materials/polymers and *in vivo* chemistry (see www.combicchem.co.uk).*



1. Optical imaging

1.1 Fluorescence

1.1.1 FRET. FRET based probes for proteases are based on the Förster Resonance Energy Transfer (FRET), process where a fluorophore (donor) in its excited state non-radiatively transfers its energy to another chromophore in its ground state through long range dipole-dipole interactions¹⁸ (or perhaps viewed more simply *via* orbital overlap). When the acceptor molecule is a non-emissive quencher such as a simple dye it undergoes relaxation to its ground state by non-emissive processes. The energy transfer efficiency is determined by the orientation/rotation of the fluorophores and the extent of overlap between the emission spectrum of the donor fluorophore and the absorption spectrum of the acceptor as well as distance, with a separation of 4 to 6 nm considered optimal for the energy transfer to be efficient,^{19,20} although molecules are non-static, and small peptides undergo large conformational changes.

Cleavage stops the energy transfer (the quenching) of the fluorophore, “turning on” the fluorescence (Scheme 1). It is vital that peptide cleavable “spacers” display high specificity towards the target protease, while the signal to noise ratio of the cleaved and non-cleaved FRET pair is high. Many routes to discover optimal substrates/spacers for FRET protease assays exist. These include a variety of combinatorial approaches (both solid^{21,22} and solution based,²³ MS substrate profiling methods,^{24,25} phage libraries²⁶ or substrate modification of known substrates, including direct screening on complex tumour tissues.²⁷ Many FRET peptide probes have been developed^{28–30} and there are reviews covering this area so here we highlight some key and novel examples^{14,19} with FRET based probes developed for legumain,³¹ thrombin,³⁰ SARS-CoV protease,³² Granzyme B³³ and Cathepsins,³⁴ among others.


Key successes in this area include improvement of the signal to noise ratio of conventional linear FRET-probes, shifting the emission into the NIR range³⁵ or by addition of chains of positively and negatively charged amino acids on opposite sides of the cleavage site that result in an “electrostatic zipper” whereby folding of the peptide brings the fluorophore and quencher into closer proximity *via* a hairpin-type structure to facilitate activity-dependent imaging.^{28,36} In these probes, not only does the hairpin enhance the quenching but the

polycationic species promotes cellular entry upon cleavage. A useful review covering this field was published by Tsien,³⁷ and clearly the concept could be extended to include oppositely charged fluorophores, that by themselves promote hairpin formation.

Some FRET probes have shown excellent applicability *in vivo*. Thus, a broad spectrum probe for detection of cathepsins using sulfo-Cy5 and QSY21 as a FRET pair was developed³⁸ and later optimized incorporating the FDA-approved dye ICG, as the NIR-emitting dye and was successfully used for fluorescence-guided-surgery in mouse and *ex vivo* in keratinocyte carcinoma.³⁹ One probe⁴⁰ (1), was recently validated for intraoperative assessment of cancer margins during surgery. It uses the same FRET pair and was designed for the detection of activated cathepsins K, L, S and B (Fig. 1a).^{41–43} A series of fluorescent FRET based probes (2) (ProSense), based on self-quenching of multiple copies of the same fluorophore (Cy5.5) within a repeating graft copolymer⁴⁴ have successfully been developed for *in vivo* imaging in animal models for the detection of MMPs, cathepsins, renin and neutrophil elastase (Fig. 1b). Recently, a tribranched FRET based probe for sensing MMP activity⁴⁵ in patients with fibroproliferative lung disease allowed *in situ* imaging of MMP activity and allowed the assessment of pharmacological action in human disease using optical molecular imaging. A “tumour painting probe” (3)⁴⁶ (Fig. 1c) has also been developed that contained a green FRET pair (FAM/Methyl Red) on opposite sides of an MMP 2/9 cleavable sequence, that produced a signal upon protease cleavage. The construct also contained a NIR fluorophore that served as an “always on” reference (sulfoCy5). Thus, activation of the probe by MMPs resulted in two signals, the reference NIR dye and the liberated carboxyfluorescein. Interestingly, once the construct was cleaved, the reference NIR dye fragment, “painted” the tumour tissue allowing tumour margin visualization on *ex vivo* tissue (Fig. 3a).

Two-photo excitation (TPE) fluorescence has attracted much attention in the area of optical imaging as it allows for deeper and more accurate localisation of the probe (the focal volume for TPE is small) but the method also needs higher power laser sources compared to one-photon technology (although at far longer wavelengths). Probes based on TPE technology have been designed for the detection of caspase 3 using the generic substrate (DEVD)⁴⁷ with the naphthalene–pyrazoline two-photon absorber coupled to a dabacyl quencher *via* a caspase 3 cleavable peptide. The construct also allowed for tuneable targetability with modification of the pyrazoline substituent accommodating a cRGD motif to target cancer cell uptake. Yan⁴⁸ developed a two-photon fluorogenic reporter for caspase-3 using two-photon absorbing nanomicelles, with the β -cyclodextrin based micelles contained the two-photon absorbing dye *trans*-4-[*p*-(*N,N*-diethylamino)styryl]-*N*-methylpyridinium iodide. The micelles were modified with caspase 3 cleavable peptides labelled with the Black Hole Quencher (BHQ-2) that quenched the emission from the micelles until cleaved by the protease.

Multi-branched scaffolds^{37,49–52} have been used to reduce probe background signals and enhance signal amplification *via*



Scheme 1 FRET probes where the light emitted by the fluorophore (F) is transferred to the quencher (Q) until the FRET is disrupted by the action of a protease causing the release of the fluorophore and restoring its emission.






Fig. 1 (a) A cathepsin reporter using the ICG/QSY21 FRET pair probe in clinical studies.⁴⁰ (b) Structure of the generic "ProSense" probe using Cy5.5 homo-labelling.⁴⁴ (c) MMP dual probe for painting tumours,⁴⁶ with cleavage generating a Cy5.5 fragment that sticks to the tumor tissue. Also note that this probe is terminated with a D-Lys residue to provide proteolytic stability.

the generation of multiple copies of the same fluorophore. This strategy initially used "self-quenching" between identical fluorophores of homo-labelled probes, where each chromophore had a dual role of being a donor as well as an acceptor.^{53,54} A self-quenching green emitting tri-branched dendrimer probe for human neutrophil elastase (HNE) was reported,⁵⁰ with the multivalent scaffold consisting of three-peptide branches specifically cleaved by HNE, each capped with a 5-carboxyfluorescein group.⁵⁵ In 2018, the concept was modified to include a quencher on each of the peptide sequences to allow the synthesis of a broad-spectrum serprocidin probe, yielding a so-called "super-silent probe" with negligible background fluorescence and much higher signal amplification.⁴⁹ More recently, optimisation of the system allowed the synthesis of a highly specific HNE probe (4, Fig. 2a), with excellent signal amplification and negligible background fluorescence that allowed visualisation of Neutrophil Extracellular Traps⁵⁵ without the need of antibodies⁵⁶ (Fig. 3b). Multivalent or dendritic FRET reporters have been reported where scaffolds are modified with FRET-peptide reporters and targeting moieties on a central core. Nagai used anionic carboxy-terminal poly-amidoamine (PAMAM) based-dendrimers (5), known to accumulate in the lymph nodes, as a core for the incorporation of a FRET substrate peptide allowing the detection of MMP-2⁵⁷ (Fig. 2b). Brennecke used a tetravalent DOTAM scaffold to

prepare probe (6) for the detection of Cathepsin S, each scaffold being modified to accommodate two copies of a cRGD tumour-directing peptide on two of the four carboxylic acids, a Cy3 on a third functionality and finally a Cathepsin S cleavable sequence containing a BHQ-2 quencher (Fig. 2c),⁵⁸ on the fourth arm. The incorporation of FRET-reporters onto/into nanoparticles as carriers, offers opportunities for novel diagnostic applications. A recent example is the development of a non-invasive nanoprobe capable of detecting granzyme B dependent transplant rejection *via* analysis of urine samples. Exposure to iron oxide nanoparticles functionalised with FRET-labelled peptides, releases the fluorescent reporter into the urine and allows identification of the onset of rejection with high sensitivity and specificity.^{59,60} Detection of multiple target proteases offers the possibility of establishing molecular signatures of diseases and therapy monitoring.⁶¹ Polydopamine nanoparticles (PDANPs) have been used as broad-spectrum quenchers and carriers of multiple fluorophore-labelled peptides.⁶² Thus, a 4-colour nano-reporter (7) was developed by assembly of four differently labelled fluorescent peptide substrates (urokinase-type plasminogen activator (uPA), MMP-2, cathepsin B, and MMP-7) labelled with AF405, FITC, Cy3 and Cy5 respectively, onto the PDANPs *via* π - π interactions with aromatic amino acid residues in the peptides/dyes (Fig. 2d). Negatively charged fluorescent PDANPs have been






Fig. 2 Dendrimer, multibranched and nanoparticle based FRET probes. (a) Tribranched probe for detection of human neutrophil elastase.⁵⁶ (b) PAMAM-based fluorogenic dendrimers for detection of MMPs. tLyP-1: tumor homing peptide.⁵⁷ (c) Tetraivalent DOTAM-based probe for detection of cathepsin S.⁵⁸ Mu: morpholine carboxamide; Cha: cyclohexylalanine. (d) 4-Colour nano-reporter for detection of uPA, MMP-2, cathepsin B and MMP-7.⁶³

used to build a system with protamine to form an aggregation-based quenching system (*via* a static quenching mechanism).⁶³ The fluorescence quenching mechanism

relying here on electrostatic interactions between the positively charged protamine and the negatively charged PADNPs with Trypsin cleavage de-quenching the system.





Fig. 3 (a) Fluorescence images delineating tumour margins using the MMP FRET probe **3**.⁴⁶ Upper row: Bright field microscopy image and fluorescence image of freshly excised lung slice, with pathologically identified adenocarcinoma (Ad), transition zone (Tr) and normal (N) tissue, following incubation with the probe. Lower row: Control tissue from the same patient sample without the addition of compound **3** was used as a measure of tissue autofluorescence within this spectral window. Reproduced from ref. 46 with permission from the Royal Society of Chemistry, copyright 2020. (b) Fluorescence microscopy image of a Neutrophil Extracellular Trap stained with HNE FRET probe **4**⁵⁶ (green), DAPI (blue) and SYTOX orange (red). Arrows indicate chromatin studded with activated probe, indicative of chromatin release by activated cells. Reproduced from ref. 56 with permission from the Royal Society of Chemistry, copyright 2021.

A probe (**8**) that allowed multiple molecular targets to be simultaneously analysed was demonstrated with a dual-enzyme probe⁶⁴ for thrombin and MMPs, allowing detection of two distinct classes of proteolytic extracellular proteins that play important roles in early carcinogenesis. The probe construct was assembled by copper mediated “click” conjugation of two FRET-labelled substrates with orthogonal excitation–emission wavelengths (Fig. 4a). Widen recently reported an AND-gate (**9**) that relies on activation by two proteases for a fluorogenic response,⁶⁵ in this system, a central fluorophore was flanked by two quencher-labelled peptides targeting different proteases, cleavage of both substrates and release of the two quenchers was required to restore the fluorescence of the central fluorophore (Fig. 4b).

Some protease-FRET probes initially used for diagnostics have been combined with therapeutic moieties to generate theragnostic entities allowing both diagnosis and therapy. Following this principle, Li⁶⁶ developed a FRET-based (carboxy-fluorescein–dabcyl) caspase 3 cleavable probe (**10**) conjugated to doxorubicin (DOX) and a targeting peptide (Fig. 4c). Enhanced delivery to the tumour tissue was enabled by the directing peptide, where the acidic pH in the cancer microenvironment (and during uptake in the endosome) triggered the release of DOX from the construct while caspase-3 cleaved the peptide resulting in a fluorescent signal. Transcription-dependent fluorogenic probes have been used for specific protease dependent activation or amplification of signal,^{67,68} while analysis kits for plasma and peripheral blood testing have been developed using polymer immobilization of FRET-based protease substrates.⁶⁹

1.1.2 Ratiometric. Ratiometric fluorescence is a method where the emission intensities at two or more wavelengths are measured. Ratiometric fluorescence detection for proteases offers benefits over quenched-FRET as it provides a reference signal allowing traceability on the distribution of the probe

with the main strategy employed for protease ratiometric detection using two target-responsive signal changes which allows concentrations to be measured. FRET between two fluorophores has been widely used to develop ratiometric probes with a donor–acceptor pair on opposite sides of a cleavable peptide.⁷⁰ In the absence of the target protease, the energy is transferred from the donor into the acceptor and only the acceptor signal is detected if the acceptor is a fluorophore (Scheme 2). Upon exposure to the target protease, cleavage results in “switch-on” of the fluorescent signal from the donor. Following cleavage, the acceptor emission will become independent of the donor.⁷⁰ Modification of conventional substrates includes the addition of directing moieties, for example, a human neutrophil elastase ratiometric FRET probe (**15**) has been reported,⁷¹ with an additional DNA minor groove binder moiety allowing successful visualization of activated neutrophils and Neutrophil Extracellular Traps (Fig. 5). A ratiometric hairpin-type probe for *in vivo* imaging has been developed that used Cy5 and Cy7 as a FRET pair and a



Scheme 2 Concept of a probe that can be used for ratiometric FRET with energy transfer between two different fluorophores that is removed upon cleavage by proteases.






Fig. 4 Multimodal probes. (a) Dual targeting probe for detection of thrombin and MMP.⁶⁴ (b) AND-gate system based on dual quenching of one fluorophore activated cleavage by cathepsins and FAP.⁶⁵ (c) Theragnostic probe for detection of caspase-3.⁶⁶ DOX: doxorubicin.




Fig. 5 *Ex vivo* mouse lung slices stained with ratiometric elastase probe **15**. (a) Confocal images of 5 μ m thick lung slices from Scnm1b-Tg mice stained with compound **15** [2 μ M] for 3 h. Scale bar: 200 μ m. (b) Quantification of NE activity using the probe donor/acceptor (D/A) fluorescence on lung slices either untreated, pre-treated with Sivelestat or with elastase for 30 min before adding the probe. Reproduced from ref. 71 with permission from American Chemical Society, copyright 2020.

solubilizing PEG moiety⁷² and was activated by thrombin. Using a similar approach, a MMP probe was developed (**11**) (Fig. 6) that is currently in Phase 2 studies.⁷³ The main drawback of this design being the background “off-target” fluorescence signal of the probe.

A ratiometric protease probe (12) was designed⁷⁴ and applied for *ex vivo* imaging of β -Secretase (BACE1) in an Alzheimer's disease mouse brain model. The reporter used the two-photon absorbing merocyanine (mCyd) as a donor conjugated to the acceptor fluorophore Alexa Fluor 633 (a sulfonated rhodamine derivative) as the acceptor *via* a β -Secretase peptide sequence (Fig. 7a).

A sophisticated assay for MMP sensing in the extracellular matrix *in vitro* (13) has been reported⁷⁵ with collagen-immobilized FRET reporters allowing the visualisation of time-dependent secreted protease activity using an extracellular matrix (ECM) collagen anchor, conjugated to enhanced green

fluorescent protein (EGFP). In this case TAMRA was attached, by intein-mediated splicing to form a collagen-adherent MMP-2 probe with a FRET pair TAMRA/GFP (Fig. 7a), linked by an MMP cleavable peptide. This strategy allowed the probe to bind to collagen in the ECM where it could interact with the secreted protease of interest, interrupting the FRET pair. The probe was validated in a 3D cell spheroid model to analyse secreted MMP-2 activity. Similarly, but by fusing the cyan fluorescent protein (CFP) and the yellow fluorescent protein (YFP) through a NE-specific cleavable linker, a neutrophil elastase fluorescent ratiometric reporter was assembled.⁷⁶

The combination of three dyes in a dual FRET system yielded a dual-target probe (14) for detection of trypsin and chymotrypsin. Using a peptide-like structure (Fig. 7b) a cascade FRET system was generated using 7-diethylaminocoumarin-3-carboxylic acid, fluorescein and rhodamine B.⁷⁷ This allowed for multiplexed assaying of protease activity.

Other strategies for ratiometric probes include a single fluorophore with tunable emission following activation by a protease, which uses the pro-fluorophore principle, where decaging of the fluorophore leads to changes in emission profile.⁷⁸⁻⁸⁰ A γ -glutamyltranspeptidase-triggered theragnostic probe was designed for cancer detection using a caged NIR photosensitiser.⁸¹ The construct when caged emits fluorescence in the NIR region of the spectrum and cannot produce ROS. Upon decaging by γ -glutamyltranspeptidase there is a shift in fluorescence emission into the yellow region which allows photodynamic therapy (PDT) due to the activity of the photosensitizer with the production of ROS at the site of activation. This field has been extensively reviewed by Huang.⁸² Du reported a ratiometric fluorescent probe⁸³ for the detection of leucine aminopeptidase (LAP) based on a quinoline derived fluorophore for imaging LAP on liver tumour cells. The probe contained a galactose moiety for targeting active tumours and a caged quinolone. The probe was internalised in cancer cells, where it was decaged by LAP, producing a red shift in emission of the construct (425 nm to 510 nm). Using a cell penetrating peptide and a substrate for caspase-3 to cage cresyl violet, a probe was generated that gave a red-shift in fluorescence emission upon caspase-3 cleavage. Recently, Cao developed the first non-peptide




Fig. 6 Structure of the clinically validated ratiometric probe AVB-620 for detection of MMPs based on the FRET pair Cv5/Cv7⁷³




Fig. 7 Ratiometric fluorescence detection of proteases. (a) Ratiometric FRET based probes for BACE1 (**12**)⁷⁴ and MMP-2 (**13**).⁷⁵ (b) dual activation-3-dye-FRET sensor providing three orthogonal fluorescence signals upon full activation of the probe.⁷⁷ (c) DNA targeting ratiometric probe for human neutrophil elastase.⁷¹

based ratiometric pro-fluorophore probe for hNE⁸⁴ using a pentafluoropropanoic acid caging group.

The use of biocompatible nanocrystals has been widely explored to build protease probes, acting as scaffolds and carriers with many offering the ability to act as spectrally broad light quenchers. Fe_3O_4 nanocrystals and quantum dots (QDs) have been widely used as FRET quenchers and carriers for the synthesis of several protease probes. Mingyuan developed a series of probes combining pH sensing with protease detection for tumour optical imaging.^{85,86} The probes (**16**, **17**) simultaneously mapping MMP-9 activity and the extracellular pH of tumours were able to target tumour cells *via* conjugation to an antibody. These were based on a modified naphthalimide as a ratiometric pH sensitive fluorophore and Fe_3O_4 nanoparticles as a quencher by covalent attachment through an MMP-9 cleavable peptide. Upon cleavage of the peptide, naphthalimide fluorescence was switched on with the ratio of the two pH-dependent emission maxima used to quantitatively determine pH (Fig. 8a). In a second-generation reporter that was used for *in vivo* imaging, folic acid was incorporated as a targeting moiety, and an ‘‘always on’’ Cy5.5 dye with an orthogonal fluorescence signal serving as an MMP-9 reporter.^{85,86}

Quantum dots (QDs) have been used as FRET donors for ratiometric sensing of proteases with fluorophore-labelled cleavable peptides immobilised as acceptors.⁸⁷ Concentric Förster Resonance Energy Transfer (cFRET) imaging is a novel application of semiconductor QDs where a central emissive QD is conjugated with multiple copies of two different biomolecular

probes. Each of these probes is labelled with one or two, similar or different, fluorophores that engage in energy transfer with the QD and, in many cases, with one another. These configurations are referred to as ‘‘concentric’’ because the dyes on the surface form a sphere that shares the same centre as the quantum dot. A recently reported cFRET QD system⁸⁸ comprised green-emitting QDs and peptides labelled with Alexa Fluor 555 (a bis-sulfonated carboxy-rhodamine) (**18**) and Alexa Fluor 647 (a bis-sulfonated Cy5). The two peptide sequences were selected as substrates for trypsin and chymotrypsin, whose cleavage modulate signal output by decreasing the number of dyes per QD. A bi-modal QD-type probe (**19**), combining charge transfer (CT) and a FRET quenching system was recently developed,⁸⁹ using QDs with a hydrophilic coating assembled with multiple copies of a number of peptides. Some were labelled with ruthenium(II) phenanthroline (Ru-phen), which quenched the QD *via* a CT mechanism, others had a distal fluorescent label, which are well-known to quench QD emission *via* FRET (Fig. 8b). Acceptor dye-labelled peptide-DNA conjugates were assembled onto the QD donors as an input gate. The addition of trypsin or chymotrypsin cleaved the peptide and altered the efficiency of FRET with the QD, and liberated a DNA output (**20.1**) which then interacted with a tetrahedral output gate (**20.2**). Downstream output gate rearrangement resulted in FRET sensitization of a new acceptor dye⁹⁰ (Fig. 8c).

1.1.3 Pro-fluorophore approach. Many widely used fluorogenic probes are based on the synthesis of ‘‘pro-fluorophores’’,






Fig. 8 Nanoparticle and QDs based ratiometric probes. (a) Fe₃O₄ nanocrystals FRET based probe systems based on quantum dots (QDs) with tumour targeting capacity using folic acid or antibody targeting and generating a pH ratiometric sensor upon cleavage by MMP-9.^{85,86} (b) QD based FRET system with a rhodamine fluorophore donor (**18**)⁸⁸ and a QD conjugated system allowing multiplexed sensing combining FRET quenching (using Cy3 as the acceptor and QD as a donor) and charge transfer quenching (using a ruthenium dye as a donor with the QD as an acceptor (**19**).⁸⁹ (c) DNA-QD-conjugated approach relying on DNA hybridisation of complementary strands, with dyes inserted into the DNA via double phosphoramidite modifications.⁹⁰

substrate-based probes that become fluorescent upon cleavage. The most widely studied and used fluorophores in this area are 7-amino-coumarins, whose emission is significantly reduced when conjugated to a peptide chain *via* an amide bond.^{91,92} The approach generally uses a protease cleavable moiety linked directly, or *via* a safety-catch (or self-immolative linker)^{93,94} with probe cleavage releasing the fluorophore (Scheme 3).

Several fluorogenic probes have been designed for the detection of N-terminal exopeptidases such as dipeptidyl peptidase (DPP-IV),^{95–97} leucine aminopeptidase (LAP), pyroglutamate aminopeptidase (PGP1)⁹⁸ or aminopeptidase N (APN)^{99,100} with attachment of the appropriate amino acid residues to a fluorophore that affects its internal charge transfer (ICT) and yields probes that switch-on upon peptidase exposure.

Dipeptidyl peptidase-IV cleaves X-Pro or X-Ala dipeptides from the amino-terminus of peptides and is known to be overexpressed in diabetes¹⁰¹ and cancer.^{102,103} Probes for detection of this protease⁹⁵ were constructed by the incorporation of a DPP-IV substrate (an amino acid¹⁰⁴ or dipeptide⁹⁶) onto a fluorophore, with quenching of its fluorescence. Urano reported a series of probes for DPP-IV detection using hydroxymethyl rhodamine green (HMRG) as a green fluorophore scaffold in combination with a series of X-Pro dipeptides,¹⁰⁵ with one of the compounds (21.1, Fig. 10a) used successfully for imaging of head and neck squamous cell carcinoma¹⁰⁶ and esophageal adenocarcinoma¹⁰⁷ (Fig. 9). Another example includes a probe that uses the NIR fluorophore SiR600,⁹⁷ conjugated to the dipeptide Glu-Pro, with the quenching mechanism relying on PeT (22.1).⁹⁷ Leucine aminopeptidase (LAP) has attracted significant attention, as it is known to be overexpressed in ovarian and breast cancer and several probes have been developed to detect its activity. Such probes are generally based on modification of the amino group of a fluorophore through an amide bond to a leucine residue (Fig. 10b). NIR hemicyanines⁹⁹ (23.1), crysol violet¹⁰⁸ (24.1), dicyanoisophorone derivatives (25.1)¹⁰⁹ or rhodamine (26.1)¹¹⁰ have all been modified to generate fluorogenic probes to





Fig. 9 *Ex vivo* fluorescent imaging of tumor tissue following spraying of DPPIV profluorophore 21.1 (a) esophageal carcinoma: a rapid fluorescent increase was observed in the tumor lesion after 30 min. Scale bar, 10 mm (b) head and neck squamous cell carcinoma tissue, upper: resected specimen observed with iodine staining shows normal mucosa (darker, periferic) vs. tumor mucosa (central area), lower: fluorescent imaging after spraying 21.1. Reproduced from ref. 105 with permission from Nature, copyright 2016 and ref. 106 with permission from Head Neck, copyright 2018.

detect this peptidase, with new approaches adding targeting capacity.¹¹¹

A small-molecule probe targeting hNE (28.1),^{112,113} a serine protease expressed in activated neutrophils in inflammatory processes, was designed where the amino group of the NIR hemicyanine dye was conjugated to a pentafluoropropanoic acid caging group, and was optically silent until de-caged by the protease (Fig. 10d).

The same concept has been extended to include so-called safety catch or self-immolative linkers, with *p*-hydroxy or *p*-amino-benzyl alcohol the most widely used. Here enzymatic cleavage releases the conjugated fluorophores and restores fluorescence.¹¹⁴ Shasha⁹⁴ developed a Granzyme B probe based on this approach for detecting T cell activation. The probe (29.1) consisted of a short peptide conjugated to a PEGylated NIR hemicyanine dye *via* a self-immolative linker. Using the same principle, a probe (30.1) for cathepsin B was developed,¹¹⁵ bearing a morpholine targeting moiety and a specific peptide connected to aminoluciferin. Based on the same self-immolative linker strategy, Chen synthesised a BODIPY-derived fluorogenic probe (27.1) with phenyl acetamide as a triggerable motif for penicillin G amidase detection.⁹³

Urano also reported γ -glutamyl-transferase (GGT) fluorogenic probes based on spirocyclic caging of γ -glutamyl hydroxymethyl rhodamine green,¹¹⁶ with activation occurring by a rapid one-step cleavage of glutamate to release hydroxymethyl rhodamine green in its ring-open, fluorescent form. A modification of this strategy¹¹⁷ added a fluoromethyl group at the 4-position of the xanthene ring (31.1). Cleavage by the protease liberates the fluoride anion to produce an azaquinone methide intermediate (31.2) that can be attacked by intracellular nucleophiles (e.g. a group on a protein) to restore the hydroxymethyl



Scheme 3 Concept of pro-fluorophore (PRO-F) activation by a protease to generate emissive molecules (F).







Fig. 10 Examples of fluorogenic probes for proteases based on pro-fluorophores for detection of (a) dipeptidyl peptidase-IV (DPP-IV) using Glu-Pro^{97,105} (21.1 and 22.1) dipeptide substrates (b) penicillin G amidase⁹³ (27.1) (c) leucine aminopeptidase (LAP) based on NIR hemicyanines (23.1),⁷⁶ crysol violet⁸⁷ (24.1), dicyanoisophorone derivatives (25.1)⁸⁹ and rhodamine⁸⁸ (26.1) (d) human neutrophil elastase (28.1)^{112,113} (e) granzyme B⁹⁴ (29.1) (f) cathepsin B¹¹⁵ (30.1) and (g) γ -glutamyl-transferase (GGT)¹¹⁷ (31.1).



diethylrhodamine (31.3) fluorescence and also trap the compound within the intracellular space, *via* conjugation to an intracellular protein.

1.1.4 AIEgen probes. Aggregation-induced emission (AIE) is a fluorescence phenomenon proposed by Tang in 2001.¹¹⁸ Most conventional organic dyes exhibit aggregation-caused quenching (ACQ) due to strong intermolecular π - π stacking when at high concentrations and internal FRET. However, AIE fluorogens (AIEgens) display weak or no emission as dilute solutions, but exhibit strong fluorescence turn-on when aggregated (Scheme 4).¹¹⁹ Restriction of intramolecular motions is recognized as the general mechanism behind AIE and as such, many AIE luminogens have structures that consist of one or more “rotors” attached to a so-called “stator”. In solution, the rotors are twisted out of conjugation because of steric congestion, but upon aggregation the rotors are prevented from undergoing free rotation and the molecule enjoys maximal conjugation, which results in the iridative emission.¹²⁰ Currently, most AIEgens are derivatives of silole, tri- and tetraphenylethenes (TPE), distyrylanthracenes (DSA) and tetraphenyl-1,4-butadienes (TPBD).¹²¹ New strategies exploiting AIEgens have been applied to protease detection, with probes that self-aggregate upon cleavage and exhibit high fluorescence emission. Classic AIEgen protease probes consist of a peptide substrate for the protease of interest with an AIEgen fluorophore that will only become fluorescent upon aggregation of several fluorophore units by hydrophobic interactions. An example of an AIEgen protease probe using tetraphenylethene (TPE) was reported by Haibin,¹²² where the fluorophore TPE was conjugated to a caspase 3/7 cleavable peptide, that prevented the dye from aggregating until cleaved by the protease (32). Some of these constructs also contained a targeting moiety *e.g.* an RGD motif for cancer cell targeting or morpholine for lysosomal localization.^{123–128}

A novel probe for real-time *in vivo* detection of MMP-13 activity in osteoarthritis was synthesized using a NIR emissive AIEgen (33) based on a cyanine–pyrene unit, which introduced a donor–acceptor system where a dimethylaminophenyl group act as an electron-donor, while nitrile and pyridinium containing units functioned as electron acceptors.¹²⁹



Scheme 4 Fluorescent activation by proteases via aggregation-induced emission.

Yuan, developed a probe for apoptosis (34) based on the sequential detection of caspases 8 and 3.¹³⁰ The probe consisted of a central peptide containing the two substrates functionalised with two AIEgens with distinctive green (caspase 8) and red (caspase 3) emissions (Fig. 11b). The green and red fluorescence were sequentially turned on when the peptide substrate was cleaved by the action of caspase-8, cleaving the TPS containing fragment, followed by caspase-3, cleaving the TPETH containing fragment, with fluorophore aggregation in early apoptotic cells (Fig. 12). In the same area, a theragnostic compound (36) targeting cathepsin B/caspase-3¹³¹ was synthesised, which consisted of three components: an RGD targeting moiety, a cathepsin B-activatable gemcitabine prodrug, and a caspase-3 specific reporter based on tetraphenylene (TPE) to give AIE.

Yuan developed a FRET-AIEgen probe (35) where a caspase-3 peptide substrate was modified with a FRET pair,¹³² with the donor being a green emitting coumarin capping the amino terminus. The acceptor, tetraphenylethenethiophene (TPETP), was attached onto the carboxy terminus of the caspase-3 peptide. The probe was silent as the acceptor fluorophore (TPETP) absorbs the energy from the coumarin, however, when caspase-3 cleaves the peptide both fluorophores are released and recover the emission of fluorescence at two different wavelengths simultaneously. The same group developed theragnostic probe combining a therapeutic moiety and an AIEgen linked though the caspase-3 cleavable peptide using a photosensitiser^{123,133} or a platinum(IV) prodrug.¹³⁴ Caspase-mediated apoptosis, induced by the concurrently released therapeutic agents, could then be measured based on the fluorescence of the released AIEgen and aggregation.

Cheng published an MMP2 activatable reporter (37) for cancer theragnostics,¹³⁵ based on a doxorubicin hydrophilic cell penetrating peptide conjugate linked through an MMP2-cleavable peptide conjugated to a PyTPE fluorophore (Fig. 11e). Upon cleavage by MMP2 the hydrophilic fragment containing DOX enters cells, while the hydrophobic part self-aggregates giving a strong yellow fluorescence emission.

An *in vitro* assay for protease activity¹³⁶ has been reported (38) that uses heparin to drive aggregation of the TPE fluorophore (Fig. 11f). Heparin, a highly sulfonated (hence negatively charged) aminoglycan induces the aggregation of the positively charged AIEgen fluorophores by electrostatic interactions, to give fluorescent enhancement. Histones have a high affinity to heparin, and can displace the fluorophores, reducing the fluorescence signal. If trypsin is added, the histones are hydrolysed and the heparin-TPE retains the fluorescence signal. Kaur developed a trypsin AIEgen probe¹³⁷ based on electrostatic interaction driven aggregation induced emission combining a negatively charged TPE dye and the positively charged protein protamine. The tetra-anionic dye, a sulphonyl-derivative of tetraphenyl ethylene (Su-TPE) is almost non-fluorescent when free in aqueous solution but protamine sulphate (PrS), an overall cationic protein, induces aggregation of Su-TPE by electrostatic interactions and leads to a highly emissive Su-TPE/PrS supramolecular complex with AIE characteristics. In the presence of trypsin, the cationic protein is






Fig. 11 Example of fluorogenic probes where protease cleavage activates AIE fluorescence. Arrows indicate cleavage site. (a) Probes for detection of Caspase 3/7 based on TPE (32)¹²² or MMP-13 based on cyanine-derivatives (33)¹²⁹ AIEgens. (b) Cascade activatable probe with sequential fluorescence signal in the green and red.¹³⁰ (c) FRET-AIEgen using a coumarin green emitting dye coupled to a TPETP AIEgen providing a dual signal upon cleavage (35).¹³² (d) Theragnostic AIEgen protease probe with a tumour targeting moiety, and different proteases mediating signal and therapeutic agent release.¹³¹ (e) Theragnostic probe that releases the drug doxorubicin (DOX) and a TPE derivative that generates an AIEgen upon cleavage by MMP-2.¹³⁵ (f) An AIEgen detection system based on negatively charged heparin and the positively charged TPE fluorophore that allows aggregation induced emission.¹³⁶

digested and the supramolecular complex disassembles, reducing the fluorescent emission.

A bimodal reporter using Gadolinium as a contrast agent for MRI combined with an AIEgen fluorophore for optical imaging was developed.¹³⁸ The probe used a DOTA-Gd³⁺ chelate that provides MRI signal enhancement, and TPE as the AIEgen linked to a caspase 3/7 cleavable peptide. In response to the protease, the Gd-AIEgen conjugate is released and aggregates leading to increased fluorescence and MRI signals.

1.1.5 Bioorthogonal. The field of chemical biology has been revolutionised by the advent of bioorthogonal reactions

– chemical transformations that can be performed in living systems without interference of biomolecules.^{139,140} This approach has been used to develop fluorogenic compounds that amplify a fluorescent signal upon bioorthogonal reactions,¹⁴¹ with protease activity used as a trigger to allow *in situ* synthesis of fluorophores (Scheme 5).

Romieu developed a reporter (39.1) whose mechanism of activation was based on pyronin assembly triggered by a protease.^{142,143} Following peptidase cleavage and decaging of an amino group, the mechanism involves *in situ* generation of an unsymmetrical pyronin *via* cyclisation/aromatization







Fig. 12 Detection of apoptotic cells using the AIEgen probe (34).¹³⁰ (a) Left: Fluorescence spectra of probe **34** incubated with caspase-8 with or without inhibitor. Right: Confocal images of HeLa cells pretreated with probe **34** and further treated with H_2O_2 and stained with Hoechst (blue channel, for nuclear DNA), Texas red/anti-casp-8 antibodies (red channel). The probe's fluorescence is detected in the green channel (by TPS AIEgen). (b) Left: Fluorescence spectra of probe **34** incubated with caspase-3 with or without inhibitor. Right: Confocal images of HeLa cells pretreated with probe **34** and further treated with H_2O_2 and stained with Hoechst (blue channel, for nuclear DNA), Texas red/anti-casp-3 antibodies (artificially labeled with green color). The probe's fluorescence is detected in the green channel (by TPETH AIEgen). Reproduced from ref. 130 with permission from Royal Society of Chemistry, copyright 2017.



Scheme 5 The concept of protease activation followed by a subsequent bioorthogonal fluorogenic labelling reaction.

cascade (39.3). This strategy offers advantages over some pro-fluorophore strategies as the fluorophore is not pre-formed (so no background signal), but one potential disadvantage is that the kinetics of the reaction might impact on the time the system takes to assemble the dye. The design principle was successfully applied to leucine aminopeptidase (LAP) and penicillin amidase (PGA). Huo developed a γ -glutamyl transpeptidase (GGT) activating two-photon fluorescent probe (40.1)¹⁴⁴ using a similar strategy. The probe could selectively detect GGT, upon cleavage, with intramolecular cyclisation resulting in a two-photon absorbing green emitting fluorophore.

Wu reported an approach using a “labelling after recognition” mechanism with phosphorescence lifetime analysis.¹⁴⁵ The approach was based on a caspase 3 specific substrate modified with two independent bioorthogonal reactive sites that allowed FRET-labelling (41.1). The strategy takes advantage of labelling the cleaved fragments and the uncleaved full peptide in the presence or absence of the protease. The novelty of this approach is that the FRET labels are added by bioorthogonal reactions following cleavage by the protease, with the

rationale that conventional FRET-labelled peptides used for protease detection are pre-labelled and the bulky fluorophores may hinder recognition and cleavage. Here, the FRET pair used was an iridium(III) complex as a donor (41.2) (attached by strain promoted alkyne–azide cycloaddition (SPAAC) and RhoB as an acceptor (41.3) (attached *via* an iEDDAC tetrazine–norbornene click reaction). In the absence of the protease, the intact peptide with the bioorthogonally reactive moieties undergoes bis-labelling of the uncleaved peptide and leads to a change in lifetime *via* FRET, with the Ir(III) complex emission quenched due to the energy transfer to rhodamine B. However, the phosphorescence lifetime of the Ir complex was not quenched when labelling occurred after cleavage.¹⁴⁵ Potential limitations of this approach could come from incomplete labelling of the full or fragmented peptide or by differing labelling kinetics in/ during the bioorthogonal labelling, an issue especially on more complex samples.

Demonstration of molecules that undergo aggregation upon activation and bioorthogonal cyclization were applied in molecular imaging (Fig. 13c) using caspase-3/7-controlled self-assembly of molecules into “nanoparticles”¹⁴⁶ as a measure of the response of cancer tissue to chemotherapy. The intramolecular cyclization was possible by reaction between a free Cys residue and a 2-cyano-4-hydroxy-quinoline (42.1) that proceeded under physiological conditions to form a thiazoline linkage. This biocompatible reaction was possible due to the reductive environment that generates the free thiol and enzyme cleavage releasing a free amino group, which then mediate the cyclisation reaction. The cyclic molecule (42.2) then aggregates forming *in situ* fluorescent NPs. This aggregation enhances retention inside the cell, increasing the *in vivo* half-life, while






Fig. 13 Examples of bioorthogonal strategies for protease detection. (a) After cleavage by the protease, caged precursor (**39.1** and **40.1**) undergo bioorthogonal addition/elimination to yield the fluorophore pyronin (**39.3**)^{142,143} or the two-photon-absorbing fluorophore (**40.3**).¹⁴⁴ (b) FRET labelling after cleavage by caspase-3.¹⁴⁵ (c) Assembling strategies based on thiazoline linkage formation in response to GSH and Caspase 3/7¹⁴⁶ or Furin.¹²⁷ (d) Excited-state intramolecular photon transfer based strategy, with cyclative cleavage following caspase-8 activation liberates the phenolic ester (**44.3**).¹⁴⁸





Fig. 14 Fluorescence images of HeLa cells treated with the bioorthogonal Caspase-8 probe **44.1**¹⁴⁸ followed by treatment with the apoptotic inducer Mitomycin C for 120 min. Left to right: Green channel (probe **44.1** (see Fig. 13d)), red channel (Mitotracker) and merged channel. Reproduced from ref. 148 with permission from American Chemical Society, copyright 2016.

the precursor units, in the absence of the protease undergo rapid clearance. The probe accumulated extensively in the cytosol allowing visualisation of apoptotic bodies in cells and tumour tissue using three-dimensional structured illumination microscopy (3D-SIM). A combination of AIE and bioorthogonal strategies were used in a probe designed for fluorescence sensing of furin activity *in vitro*.¹²⁷ The probe (**43.1**) was cleaved by furin exposing a free 1,2-aminothiol unit (**43.2**) that reacts with the cyano group on a cyanobenzothiazole motif yielding the more hydrophobic dimer (**43.3**) which self-assembles into fluorescent NPs.

A fluorescent activatable caspase-8 probe, consisting of an ESIPT (excited-state intramolecular photon transfer¹⁴⁷) fluorophore attached to a Cys-residue has been reported.¹⁴⁸ These ESIPT fluorophores produce insoluble fluorescent aggregates with fluorophores localized in close proximity to the enzyme with enhancement of fluorescent emission – a process that is similar, but different to AIE. The protease probe was synthesized by a thiol-1,4 addition reaction¹⁴⁹ of a Cys containing peptide (caging group) with an acryloylated fluorophore (**44.1**). Upon internalisation of the probe in cells, cleavage of the peptide by activated caspase-8 results in intramolecular bioorthogonal cyclisation, liberating the amino group which reacts with an ester to release a 1,4-thiazepine seven-membered ring (**44.2**).¹⁵⁰ Decaging the fluorophore (**44.3**) switches on bright green fluorescence by excited-state intramolecular photon transfer, allowing high-sensitivity and high-resolution imaging (Fig. 14).

1.2 Chemiluminescence

Chemiluminescence (CL) is a powerful imaging technology that requires no external light source, does not suffer from photo-bleaching and has negligible background luminescence, but each molecule will only produce one photon. The phenomena of chemiluminescence can be defined as the emission of light resulting from a chemical reaction (Scheme 6) and differs from fluorescence in that the generation of the excited state arises thanks to the energy of a chemical reaction and does not depend on light irradiation.¹⁵¹ The field of chemiluminescence



Scheme 6 The concept of protease activatable chemiluminescence.

for imaging applications has grown rapidly with the discovery of several natural and new synthetic luminogens.^{152,153}

Synthetic chemiluminescent systems take inspiration from natural bioluminescent systems that generate light following two sequential reactions, firstly oxidation of a substrate by an oxidizing agent or an enzyme into a “high energy intermediate” and secondly, the rapid decomposition of this intermediate in a process that produces light, with the Luciferin/Luciferase/O₂ system being the most studied.¹⁵⁴

In the last decade, the field of chemiluminescence for imaging *in vivo* has expanded with synthetic modification of the natural luminogens to move beyond the limitations of natural luciferin.^{155,156} This includes tuning the emission properties of the natural luciferin substrate to improve its quantum yield and give NIR emission by increasing the conjugation of natural D-luciferin^{157–160} or by exploiting FRET with red shifted fluorophores.¹⁶¹ Caging of luciferin by the addition of a triggerable protecting group to the 6'-OH/NH₂ group generates a non-recognisable substrate for luciferase (**45.1**) allowing for turn-on of signal upon protecting group removal by the given trigger (e.g. enzyme or analyte). This strategy has been adopted to develop luminogenic probes for proteases such as cathepsin B (**46**),¹⁶² chymotrypsin (**47**),¹⁶³ carboxypeptidases A and B (**48**),¹⁶⁴ Caspase-1 (**49**)¹⁶⁵ and furin (**50** and **51**)¹⁶⁶ (Fig. 15a). A novel strategy was devised with the *in situ* bioorthogonal assembly of firefly luciferin,¹⁶⁷ the design consisting of two complementary caged precursors of luciferin, a peptide-based probe (**52.1**) that released D-Cys in the presence of Caspase-8 and a boronic acid probe (**52.3**) that released 6-hydroxy-2-cyanobenzothiazole upon reaction with H₂O₂ (Fig. 15b). Once decaged, the two precursors undergo a bioorthogonal condensation reaction to form D-luciferin (**52.5**), with cyclisation between the carbonitrile and the thiol group of D-cysteine, thus reporting simultaneously oxidative stress (H₂O₂) and inflammation (caspase-8). Another approach focused on the *in situ* assembly of the enzyme luciferase (instead of the luciferin substrate) was engineered by Talley.¹⁶⁸ A modified luciferase specifically activated by Caspase-1 was generated by inserting a known target sequence into a “circular luciferase”. Cleavage by Caspase-1 allowed the generation of a functional luciferase thus, generating a bioluminescent system.

Natural bioluminescent organisms can modulate the colour of light emitted by the same principles as FRET by coupling luciferase to fluorescent proteins with overlapping spectral properties.¹⁶⁹ Bioluminescence resonance energy transfer






Fig. 15 Examples of protease probes based on chemiluminescence. (a) Probes based on decaging of aminoluciferin, a substrate for fLuciferase that produces luminescent oxyaminoluciferin (b) bioorthogonal assembly of D-luciferin *in situ* requiring dual activation by Caspase-8 and hydrogen peroxide.¹⁶⁷ fLuc: firefly luciferase.

(BRET) systems for protease sensing take advantage of the luciferin-luciferase system as an energy/light donor for fluorescent acceptors (generally GFP) and commonly use an optimised luciferase-substrate system coupled to a fluorescent protein through a protease cleavable linker. Upon cleavage and energy transfer, emission from the fluorescent molecule stops and the emission corresponds solely to the bioluminescent luciferase.^{170–173} The original systems used a blue emitting luciferase and GFP, but in 2020 the first red-shifted BRET probe for detection of plasmin was reported.¹⁷⁴

In an effort to simplify the system and remove the need of the enzyme luciferase for oxidation of D-luciferin, Shabat developed a series of caged 1,2-dioxetane phenols (53.1 and 53.2), highly stable compounds that rely solely on decaging of the dioxetane phenol-protecting group to produce luminescence.^{175,176} Upon interaction with the decaging target trigger, an unstable phenolate-dioxetane intermediate (53.3) is released producing the excited ester (53.4) that relaxes with photon emission (Fig. 16a). Caging of 1,2-dioxetane intermediates have been widely used for protease sensing and generally use a protease sensitive peptide conjugated to the 1,2-dioxetane *via* a safety catch or self-immolative linker (54 and 55).^{177,178} The emission properties of the 1,2-dioxetane can be tuned by

increasing the conjugation of the phenolate, adding a conjugated π system and an electron withdrawing group (EWG) at the *ortho*-position.¹⁷⁹ Using this strategy, chemiluminescent Cathepsin B probes were designed (56–58), that showed high sensitivity¹⁸⁰ with enhanced tumour penetration by linking to a tumour targeting peptide.¹⁸¹ Recently, the speed of chemiexcitation was also improved, allowing for greater light emission efficiency and better signal/noise ratios, by modifying the *ortho*-phenol EWG functionality to an α,β -unsaturated carboxylic acid functionality. Using this system, a Granzyme B probe (59), that could detect natural killer cell activity in live mouse models tumours,¹⁸² was developed (Fig. 17). Using a similar strategy, Bogyo developed a system for detection of M. Tuberculosis,¹⁸³ that uses a chemiluminogenic FLASH probe bearing the substrate of Hip1, a protease of Mtb (Ac-Igl-(4-Cl-Phe)-Lys-Leu), where Igl is a the non-natural amino acid H-(2-indanyl)Gly-OH. This probe (60) allows detection and quantification of Mtb in human sputum samples *in vitro* and, importantly, the system can differentiate between live and dead bacteria. As such it shows real potential as a point-of-care sensing platform, as do the PSA probes (61) developed by Shabat that allows on-site measurements using a small portable luminometer.^{184,185}






Fig. 16 Examples of protease probes based on chemiluminescence. (a) 1,2-Dioxetane phenols relying on decaging of the dioxetane phenol-protecting group to produce luminescence from initial probes for Caspase 3 and PGA.^{177,178} Optimisation of light emission efficiency by increasing the conjugation of the phenolate in probes for cathepsin B,^{180,181} Granzyme B¹⁸² or PSA.^{184,185} Ac: acetyl group; Mu: morpholine carboxamide moiety. (b) Chemiluminescence Resonance Energy Transfer (CRET) strategy for detection of MMP activity utilising a phenoxy-dioxetane luminophore and a nitro-dabsyl quencher.¹⁸⁷

Modifications of the emission capabilities of 1,2-dioxetane probes by the addition of a fluorophore substituent at the *meta*-position of the benzoate unit allowed significant amplification of the signal thanks to transfer of light from the emission of the chemiluminogen to the fluorophore by Chemiluminescence Resonance Energy Transfer (CRET) (Fig. 16b). A model

galactosidase triggerable probe¹⁸⁶ has been reported with great potential for applications in protease sensing by replacing the galactosidase moiety by a cleavable peptide.¹⁸⁷ Using CRET, a phenoxy-dioxetane luminophore attached to a 7-hydroxycoumarin scaffold was developed and linked to a quencher-peptide construct. The coumarin-dioxane luminogen




Fig. 17 (a) Chemiluminescence spectra of granzyme B chemilumino-genic probe **59¹⁸²** following incubation with granzyme B (green line) or without enzyme (black line) or with a granzyme B inhibitor (red line). (b) *In vivo* representative chemiluminescence image of an NSG mouse containing MDA-MB-231-xenograft tumours where NK-92 cells were adoptively transferred. Only the right tumour (red arrow) was injected with NK-92 cells with the left tumour being NK cell-free. After 8 h of the NK cell injection, probe was injected into both tumours. Reproduced from ref. 182 with permission John Wiley and Sons, copyright 2021.

exhibits intense and persistent chemiluminescence (62). Following the same principles as FRET conjugation of a non-emissive quencher acceptor molecule to the luminogen quenches any chemiluminescence emission until the peptide is cleaved by the protease.

1.3 Optoacoustics

Photoacoustic imaging (PAI) is an imaging strategy that bridges the traditional limited penetration depth and the resolution limits of diffuse optical imaging. Some reviews have been recently published^{188–190} and thus here we will only report on very recent papers, applications and novel concepts.

In photoacoustic imaging, a laser pulse is used to “illuminate” specific structures in the body by virtue of them containing molecules that absorb photons. This causes local heating that generates pressure waves (the thermoelastic effect due to vibrational and translational relaxation). These pressure waves are in the ultrasound frequency range and as such can be measured by traditional ultrasonic transducers to generate an image. Photoacoustic imaging has rapidly been adopted in preclinical *in vivo* imaging in small animals for a range of disease indications, where it has provided in a non-invasive manner, images that in essence show where optical energy has been absorbed by detection of the acoustic waves generated. A key attribute is that it can do this at depths of several centimetres while offering a resolution of ~ 100 μm .

PAI can exploit the absorption capacity of naturally occurring molecules, such as haemoglobin¹⁹¹ and melanin,¹⁹² however, probe-based contrast agents are now being used to allow directed “molecular photoacoustic imaging” at greater depths (Fig. 18). Typical molecules used in PAI have included indocyanine green (ICG) and methylene blue (MB) and some take advantage of both the photoacoustic and the fluorescence signals. The combination of optical and photoacoustic imaging has become a widely implemented strategy (Table 1).^{193–195}

Traditional non-fluorescent dyes of various types are actually more efficient in terms of conversion of light absorption into heat and acoustic signals^{196,197} (simplistically it is better that light is converted to heat and not emitted as a photon). Thus, dyes offer greater thermoelastic expansion than fluorochromes, making quenchers *e.g.* dabsyl and the so-called black-hole quenchers (BHQ) good candidates for photoacoustic contrast agents but any dye with a high extinction coefficient and good conversion of light to heat should work well as contrast agents





Fig. 18 Examples of some contrast agents and strategies for photoacoustic imaging.





Scheme 7 The concept of photoacoustic probes activated by proteases.

for PAI. One PA contrast agent reported recently used BHQ-1 conjugated to a cRGD targeting moiety.¹⁹⁸

Recently, activatable photoacoustic imaging contrast agents have appeared. Design of these probes utilize similar approaches to those discussed for fluorescence base probes (FRET, self-assembly/bioorthogonal, pro-PAI, AIEgens), generating a specific switchable signal upon alteration of their structure, with proteases allowing disease-specific targeting/activation (Scheme 7).

NIR fluorescent dyes can act also as photoacoustic agents. MMP-Prosense 680,¹⁹⁹ the NIR probe previously described, was evaluated for photoacoustic imaging, achieving high-resolution mapping of MMP activity deep in vulnerable plaques of intact human carotid specimens. Multispectral optoacoustic tomography allowed three-dimensional reconstruction of targeted structures *in vivo*²⁰⁰ with morphologies similar to heterogeneous MMP activity but with better than 200 μm resolution throughout intact plaque tissues and allowing volumetric images of activatable molecular probe distribution deep within optically diffuse tissues.

Levi²⁰¹ developed a FRET-based protease activatable PAI probe using an AF750/BHQ-3 labelled MMP-2 cleavable peptide that under physiological conditions generates two photoacoustic signals. Cleavage/activation generates a BHQ-3 labelled cell penetrating peptide that results in accumulation of the PA contrast agent into cancer cells and a NIR dye labelled fragment that produces orthogonal photoacoustic signals.

Using a similar approach to that covered in the pro-fluorophores section, a urokinase-type plasminogen activator (uPa) activatable probe was designed²⁰² that provides a turn-on in fluorescence and photoacoustic signals and optimal renal clearance due to the hydrophilicity dextran backbone. The probe consists of a “caged” dextran functionalised-Cyanine dye, connected to a cleavable uPA peptide sequence *via* a self-immolative linker. Upon cleavage by the protease, the dye is decaged and its fluorescent and photoacoustic properties restored. Using the same strategy, a probe for dual imaging of acute kidney injury, cleavable by γ -glutamyl transferase (GGT), was developed by Chen (63, Fig. 19a),¹⁹⁴ allowing real-time imaging of kidney function at a molecular level (Fig. 20).

CuS nanoparticles, exhibit strong (broad spectrum) absorbance, and have been used as photothermal agents for tumour ablation. As might be anticipated from their “black colour” they absorb broadly and show strong photoacoustic signals at 930 nm. A probe based on a BHQ-3 labelled MMP-cleavable-peptide conjugated to CuS nanoparticles was developed,²⁰³ that provided a combination of two PA signals in absence of the MMP. Upon cleavage by the protease, only the PA signal from the nanoparticles remained. The probe successfully sensed MMP-activity in mice in a promising alternative to optical imaging techniques with improved detection depth. Due to their strong and tunable optical absorptions gold-based nanoprobes have been widely used as PAI agents. Probes have been developed that produce a change in the emitted PA signal and produce combined fluorescence signals in response to proteases. Using a nanocage, a probe for MMP-2 was developed,²⁰⁴ which produces a strong acoustic signal at 800 nm. In the intact construct fluorescence emission by the Alexa Fluor 680-conjugated peptide was quenched by the gold nanocage and producing a PA signal by illumination at 680 nm indirectly. Upon MMP cleavage, the NIR dye is released and cleared from the tumour tissue which results in changes in the photoacoustic spectral signature, going from a signal contributed by both reporters to one generated by the gold nanocage alone.

An optoacoustic activatable probe²⁰⁵ with capacity for simultaneous photoacoustic and NIR optical imaging based on a self-assembly strategy activated by protease cleavage, driven by

Table 1 Photoacoustic probes

Modality	Contrast agents	Strategy	Protease	Sequence	Ref.
Optoacoustics	Cy5.5 dimer	FRET	MMPs	Ac-K(PEG)-[K(PEG)-K(Cy5.5)) K/K(Cy5.5)-K(PEG)] _n ⁻	199
	Alexa750/BHQ-3	FRET	MMPs	Not reported	201
	Hemicyanine	De-caging	GGT	GGR	194
	Cy5.5/QSY21	Self-assembly	uPa	γ -Glu	202
Photoacoustics	CuS nanoparticles/BHQ-3	FRET	MMPs	KCPLGVGRGY	203
	Gold nanocages/Dye 680	FRET	MMPs	GLPGVGRGKGG	204
	Purpurin 18	Self-assembly	Gelatinase	GKGPLGVRC	206
	ATTO740	Bioorthogonal	Furin	PLGVRG	207
	ICG	Bioorthogonal	Caspase-3	RVRRC	208
	Gas Vesicle Protein (GvpC)	Buckling of the GvpC	TEV	DEDV	209
PA/PTT/PDT	Gold nanostars/IR - 780	FRET	MMPs	ENLYFQG	210




Fig. 19 Dual and aggregation based optoacoustic activatable probes. (a) Dual imaging, fluorescence/photoacoustic probe for detection GGT, cleavage by the protease degrades a cyanine dye with fluorescence and photoacoustic properties.¹⁹⁴ (b) Amphiphilic construct using QSY21 as a photoacoustic agent and sulfonated Cy5.5 as a fluorophore. Amphiphilicity of the construct drives nanoparticle formation, while cleavage by MMP-2 disassembles the nanoparticles and results in a change in photoacoustic signal.²⁰⁵ (c) Bioorthogonal photoacoustic emissive oligomer forming probe for furin.²⁰⁷ (d) Dual activation dependent probe for sensing of GSH and caspase-3 that results in photoacoustic emissive nanoparticle assembly.²⁰⁸

hydrophobic interactions has been reported. The probe was constructed with a near-infrared dye (Cy5.5) and a quencher (QSY21) linked through a peptide substrate of MMP-2. The

construct is amphiphilic as QSY21 is highly hydrophobic while sulfonated Cy5.5 is hydrophilic, which drives self-assembly into nanoparticles. When cleaved by the protease enhanced NIR






Fig. 20 PA imaging of cisplatin-induced Acute Kidney Injury using a γ -glutamyl transferase optoacoustic probe (63).¹⁹⁴ Mice transverse section after i.v. injection of the probe in different treatment groups (detection at 700 nm). The white circles indicate the two kidneys. RK, right kidney; LK, left kidney, NAC: N-acetyl-l-cysteine protected. Reproduced from ref. 194 with permission John Wiley and Sons, copyright 2021.

fluorescence is generated, simultaneously with photoacoustic signal ratiometric changes as the nanoparticle-assemblies disaggregate. Photoacoustic emissions from the intact construct were detectable with high intensity at 680 nm and at 730 nm. Upon cleavage, a reduction in the 680 nm photoacoustic signal was observed in an MMP concentration dependent manner with the corresponding increase in fluorescent emission by the de-quenching of Cy5.5 (the photoacoustic signal at 730 nm remained constant (MMP independent) and served as a reference signal (64, Fig. 19b). Following the same mechanistic principle (but in reverse), a self-assembling gelatinase probe used Purpurin 18 as the functional photoacoustic stimulator²⁰⁶ with self-assembly upon protease cleavage leading to the formation of photoacoustic emitting nanofibers. Another PAI self-assembling probe (65.1) for detection of furin has been developed where cleavage leads to the formation of photoacoustic emissive oligomers *via* a bioorthogonal reaction.²⁰⁷ The activation of the probe *via* furin cleavage of the peptide substrate released (ATTO740)-1,2-aminothiol that undergoes self-condensation to form oligomers (65.3) containing ATTO740 (Fig. 19c). These nanostructures enhance the quenching effect of the fluorophores thus minimizing radiative emission, which increases the photoacoustic signal. The same bioorthogonal reaction was used to design a caspase-3 probe.²⁰⁸ In this case dual activation was dependent on caspase-3 and glutathione (GSH). The construct (66.1) contained a cyano-6-hydroxyquinoline (CHQ), a D-Cys residue, a caspase-3-cleavable peptide substrate (DEVD), ICG and contained a cRGD targeting peptide (Fig. 19d). Owing to aggregation-caused quenching (ACQ) the nonradiative relaxation process was favoured, which increased the PA signal and decreased the fluorescence of ICG.

Anupama recently developed photoacoustic probes for the detection of proteases²⁰⁹ consisting of engineered gas vesicle based biosensors, air-filled protein nanostructures that change their ultrasound contrast in response to the activity of different biomolecules. In this case, they used tobacco etch virus protease (TEV). In presence of the protease, the gas vesicle shell becomes less stiff, thereby allowing it to undergo buckling and produce enhanced nonlinear ultrasound signals that can be easily distinguished from the intact, non-digested “gas vesicles”.

A theranostic approach based on gold nanostars was developed²¹⁰ with multiple and simultaneous imaging


modalities. The probe consisted of a gold nanostars core (photoacoustic and photothermal effector), conjugated to the MMP-2 peptide (Ac-GPLGIAGQ) *via* BSA loaded with a NIR dye IR-780, for optical imaging and photodynamic therapy.

2 Bench-top or *in vitro* applications

2.1 Colorimetric

Colorimetric sensing determines the presence or absence of target analytes by measuring optical density (Beer–Lambert law) and depends on the generation of coloured species. Due to the advantages of simple operation with no need for complicated instrumentation, colorimetric sensing offers a good strategy for point-of-care diagnosis with test results that can be interpreted with the naked eye (classic examples are Gram staining of bacteria). This is useful in terms of speed of analysis, and the reduction in the cost of testing in resource-limited settings where sophisticated technologies and time delays would limit application. In the field of protease sensing, there are two main types of colorimetric probes used: colorimetric probes based on enzyme-catalyzed organic chromogenic substrates that form coloured products²¹¹ and biosensors based on modification of the surface plasmon resonance (SPR) of noble metal nanoconstructs.²¹² Indeed gold nanoparticle (AuNPs) colorimetric assays are the most widely used with many publications over the past 30 years taking advantage of the AuNPs excellent tunable properties as simple chromophores²¹³ with the optical properties of AuNPs depending on the SPR of the nanoparticles.²¹⁴ Modifications of the surface of the AuNPs can induce or prevent aggregation, which correlates with changes in the SPR that leads to a colour dependence (Scheme 8). The surface of the AuNPs are usually modified using thiol-gold chemistry to simultaneously add specific molecular recognition moieties and to tune the stability of the particle suspension. Surface modification of the construct by targeted biomarkers can trigger changes in the aggregation behaviour of the AuNPs that can be visible by the naked eye as a colorimetric response. Generally the aggregated particles give rise to a distinct purple colour, while the dispersed AuNPs look red. A simple protease colorimetric probe can thus use peptides conjugated to AuNPs²¹⁵ *e.g.* *via* thiol chemistry or by electrostatic interactions, with cleavage of the peptide resulting in either induction or prevention of





Scheme 8 The concept of colorimetric sensing based on gold nanoparticle aggregation in response to the presence of proteases.

aggregation that results in a change in colour. The systems based on AuNPs aggregation can use a “mix and detect” system where standard unmodified gold nanoparticles (generally stabilised with citrate) are mixed with a peptide. Alternatively, gold nanoparticles may be pre-modified, where the protease substrate peptide is immobilised on the surface of the nanoparticles which can then generate a visual response based on the exposure to (or lack of) the protease.

A probe for MMP-7²¹⁶ was synthesised (67) using pre-modified gold nanoparticles using a C terminal Cys peptide substrate for the protease. The negatively charged peptide sequence prevented aggregation of the AuNP until cleavage by the protease, that removed the negatively charged residues causing a reduction of the net charge and decrease in nanoparticle size, leading to a loss in stability of the nanoparticles that would aggregate and shift from red to purple; a colour shift detectable by the naked eye. A mix and detect system (68) used unmodified free gold nanoparticles (citrate stabilised, negatively charged) and a caspase-3 cleavable peptide.²¹⁷ The peptide contained two adjacent Cys at the C terminus, three negatively charged residues and one positively charged arginine. When the peptide was pre-incubated with the protease, the three negatively charged residues were cleaved off, leaving a net positively charged thiol fragment that would be immobilised on the gold nanoparticle *via* the cysteine side-chains and induce aggregation (due to interaction between the positively charged arginine and remaining negatively charged areas of the AuNPs). When the free AuNPs were incubated with the mixture of peptide and protease, a blue colour would be observed due to aggregation whilst the incubation with the intact peptide and no protease prevented aggregation retaining the initial red colour.²¹⁷ Chen²¹⁸ reported a probe for MMP-2 (69) following a similar strategy with the negatively-charged fragment on the N terminus (as a Glu₄ moiety) and the positively charged residue being Lys on the thiol containing fragment.

Conjugation by electrostatic interactions has used peptides containing high levels of positively charged residues that coordinate with the free negatively charged AuNPs (citrate stabilised) in suspension. Using this approach, a colorimetric assay for trypsin was reported (72)²¹⁹ that used a hexa-Arg

peptide as both a substrate for trypsin and to allow conjugation to the nanoparticles. When the free (negatively charged) nanoparticles are exposed to the positively charged peptide, the peptide intercalates between gold nanoparticles and induces cross-linking and aggregation of Au-NPs leading to the red-shift. If, however, the peptide is pre-incubated with enzyme prior to exposure to the nanoparticles, the peptide is digested, and the nanoparticles remain dispersed. Another probe using electrostatic conjugation was reported²²⁰ which used negatively charged carboxyl-functionalised AuNPs (using a carboxy-PEG₁₂-thiol) in combination with a MMP substrate with hexa-His tags at both ends (metal ions drive metal-affinity coordination between the carboxyl groups and the His-tags). The intact peptide therefore drives aggregation whilst the cleaved peptide promotes the dispersion of the nanoparticles.

Ding²²¹ used a “mix and detect” trypsin (70) assay with a peptide bearing a Cys residue at the C-terminus and a positively charged Lys at the P1 position. Since the oligopeptide contains both Cys and a positively charged Lys residue, it causes aggregation of the citrate-stabilised, negatively charged, AuNPs. However, since trypsin cleaves the peptide, separating the Cys and Lys residues, the cleaved oligopeptide no longer causes aggregation of the AuNPs.

Meng-Qi reported a novel strategy²²² allowing the properties of the SPR to be tunable *via* the modification of gold nanorods (AuNRs) (Fig. 21c). This protease detector (71.1, 71.2, 71.3) was based on a protease specific peptide with two central Cys residues at the cleavage site. Cleavage by the protease thus releases two fragments exposing the monothiol groups from the Cys, that are otherwise non-accessible, and react with the AuNRs causing morphological changes, with “new spikes” formed by addition of the peptides fragments to the surface, resulting in unique SPR peak shifts that were also seen by the naked eye (red-to-blue). Using this strategy, the group developed a probe for the detection of trypsin activity in a label and instrument-free manner and with ultrahigh sensitivity, with a LoD of 60 fM.

A colorimetric method for prostate-specific antigen (PSA) detection was developed by Liu²²³ using the formation or inhibition of formation of AuNPs as a colorimetric indicator. The method was based on ascorbic acid induced formation of AuNPs, a process that can be inhibited by the presence of Cu²⁺. HAuCl₄ (74.1) can be reduced to form AuNPs (74.2) by ascorbic acid (73.1), however, in the presence of Cu²⁺, ascorbic acid is oxidised (73.2), and can no longer reduce the HAuCl₄. The designed construct was based on peptide coated gold magnetic microbeads containing a Cu²⁺ binding triad (Asp-Ala-His) followed by a PSA cleavable sequence (Fig. 22a). When the protease is present, the peptide is cleaved and the Cu²⁺ binding triad released. Consequently, the copper ions are not trapped, resulting in oxidation of ascorbic acid and no AuNP formation. Alternatively, the Cu²⁺ binding triad can be localized internally so that it remains masked (Fig. 22b), but can be demasked by proteolytic hydrolysis (β-secretase) exposing the Cu²⁺ chelating ligand. In this design, formation of AuNPs only happens in the presence of the protease.²²⁴






Fig. 21 Examples of protease colorimetric assays based on gold nanoparticles. (a) Premodified gold nanoparticles conjugated to a cysteine terminal cleavable peptide for MMP-7.²¹⁶ (b) Mix and detect strategies based on gold nanoparticles and stabilising peptides (with destabilising effect if protease is present) for detection of caspase-3,²¹⁷ MMP-2²¹⁸ or trypsin.²²¹ (c) Mix and detect method based on tunable SPR of gold nanorods (AuNRs)²²² using a protease specific peptide with two central Cys residues at the cleavage site. Cleavage by the protease causes morphological changes, with “new spikes” formed by addition of the peptides fragments to the surface via newly exposed thiol groups. (d) Colorimetric assay for trypsin²¹⁹ that uses a hexa-Arg peptide as both a substrate for trypsin and to allow aggregation of the nanoparticles. When nanoparticles are exposed to the positively charged peptide, the peptide intercalates between Gold nanoparticles and induces aggregation of Au-NPs leading to the red-shift, which is prevented when the peptide is digested by trypsin.

Bhatia reported on the design and synthesis of protease probes for pre-clinical use developing a series of colorimetric assays/platforms as diagnostics tools for detection of disease related proteases. They used a variety of peptide-modified platforms that can be administered intravenously, activated at the site of the disease and detected in the urine. The urinary, colorimetric, *in vivo* assay²²⁵ conjugates gold nanoclusters (AuNC) to a carrier protein (neuroavidin) tethered to a protease cleavable peptide with a Cys residue for binding to the AuNC (76–79). Exposure to the protease (thrombin or MMP) at the disease site, following IV administration,

resulted in the release of the AuNC from the construct enabling passage into the urine to produce a direct colorimetric readout of the disease state. The strategy exploited the peroxidase capacity of the ultra-small AuNC, with a size <2 nm that also showed efficient filtration capacity through the kidneys into the urine. These AuNCs had an intrinsic catalytic peroxidase activity, catalysing the oxidation of 3,3',5,5'-tetramethylbenzidine (TMB) (75.1), that could be monitored by absorbance at 652 nm (Fig. 23a).

Zourob designed a series of low-cost, easy-to-handle, highly sensitive and portable colorimetric biosensors (Fig. 24) capable




Fig. 22 *In situ* formation of catalytic AuNPs. (a) Colorimetric assay for detection of PSA based on *in situ* synthesis of gold nanoparticles from the precursor HAuCl_4 catalysed by ascorbic acid in absence of $\text{Cu}(\text{II})$.²²³ The design used peptide-modified magnetic nanoparticles containing a Cu^{2+} binding triad. The peptide was cleaved by PSA and the Cu^{2+} binding triad released. Consequently, the copper ions are not trapped, resulting in oxidation of ascorbic acid and no AuNP formation. (b) System with the Cu^{2+} binding triad is localized internally and demasked by proteolytic hydrolysis (β -secretase) exposing the Cu^{2+} chelating ligand. In this design, formation of AuNPs only happens in the presence of the protease.²²⁴ MB: magnetic beads. AA: Ascorbic Acid.






Fig. 23 Small molecule based systems for colorimetric sensing of proteases. (a) Urinary colorimetric *in vivo* assay²²⁵ using gold nanoclusters (AuNC) attached to a carrier protein via a protease cleavable linker. Exposure to thrombin or MMP-9 releases AuNCs to produce a direct colorimetric readout exploiting the intrinsic catalytic peroxidase activity of AuNCs to oxidise TMB. (b) Engineered procaspase-3 is auto-inhibited in the absence of the target protease (MMP-2) by a weak reversible inhibitor attached to the enzyme by a peptide linker. Upon activation by MMP-2 active caspase-3 is generated that cleaves the substrate Ac-DEVD-pNA generating a chromogenic response.²³¹

of detecting different disease-related proteases (82, Fig. 24). The method used a probe that consisted of a specific peptide substrate covalently attached to magnetic beads through its N-terminus and linked to a gold probe surface at the C-terminus *via* a Cys residue. This construct resulted in a layer of magnetic beads adsorbed on the probe surface masking its golden colour in the absence of the protease. Upon protease cleavage the peptide linkage between the magnetic beads and the gold probe surface is lost and the released magnetic beads were magnetically collected and analysed. This idea was applied to develop portable probes for PSA,²²⁶ HNE and Cathepsin G,²²⁷ Listeria monocytogenes protease²²⁸ and *P. aeruginosa* proteases.²²⁹

Small molecules have found successful applicability in this area with *p*-nitroaniline (pNA), a well-known reporter. Thus, chromogenic peptides, conjugated to pNA (80.2) have been used for colorimetric-based testing, which when conjugated are colourless, but upon cleavage result in a colorimetric

response.²³⁰ An interesting strategy was developed by Dokyung, where an engineered procaspase-3 was modified to be auto-inhibited in absence of the target protease (MMP-2) by adding a weak reversible inhibitor linked to the enzyme by a peptide linker (81) that was cleaved by the protease of interest (Fig. 23b). This cascade system also used a chromogenic caspase-3 substrate (Ac-DEVD-pNA, 80.1) to generate a chromogenic response with its hydrolysis rate reporting on MMP-2 activity.²³¹ Using pNA-peptides, immobilised on cellulose, a paper-based chromogenic probe to detect inflammation was developed.²³²

2.2 MS based detection

MS has been used as a method for a variety of proteomic analysis studies including as a diagnostic tool to differentiate disease from healthy profiles as well as staging and disease monitoring. Proteome profiling for diagnostic purposes is a thriving area in proteomics, however, the complexity of the




Fig. 24 Colorimetric sensing platform for HNE and Cat G.²²⁷ These probes consist of specific protease substrates covalently bound to a magnetic bead at one end and to a gold surface by the other. Cleavage by the protease results in dissociation of the magnetic bead complex. A magnet placed on the back of the strip (see arrow) attracts the cleaved beads that are displaced exposing the gold color. HNE sequence: -GSGSGGGAAPVAAKGGGSGSC- (82.1) and cathepsin-G sequence: -GPQGIWGQR- (82.2). Reproduces with permission of the American Chemical Society, copyright 2015.

samples and the inter-individual (not disease-related) heterogeneity poses challenges.²⁴ Analysis of proteases *via* activity profiling has attracted significant attention, but the complexity of samples still poses a problem. Certain proteolytic fragments, from high abundant serum proteins, are potential markers of tumour-specific proteolytic activity that can be analysed in blood/serum specimen, but they present a significant analytical challenge. This problem can be circumvented using exogenous synthetic substrates. Thus, “spiking” exogenous reporter peptides into biological samples for the characterization of protease activity offers substantial advantages over profiling of ‘native’ proteomic serum. These reporter peptides allow accumulation of signal to levels that are readily detectable with MS and eliminate the background signal provided by high-abundance ‘native’ proteins or peptides in the sample (Scheme 9).²⁴ When reporter peptides are added to the specimen, the proteolysis of these exogenous reporters produces a unique MS spectrum that will be different in the absence or

presence of the protease (excess reporter peptides are necessary not only to ensure substrate saturation, but also to displace competing natural substrates from any tumour-associated proteases).²³³


The use of isotopic MS tags has greatly simplified analysis of complex samples with tagging of freshly generated peptide fragments prior to separation and analysis allowing quantitative MS/MS analysis of digested peptides. The first isotope-based MS tags for peptides incorporated stable heavy isotopes such as ¹³C, ¹⁵N, ¹⁸O and ²H with initial tags consisting of a duplex system with “heavy/light” isotope tags,²³⁴ allowing comparison of two different conditions (Table 2).

ICAT (Isotope-Coded Affinity Tags)²³⁵ is an isotopic, duplex system of MS tags that contain a biotin moiety that allows isolation by affinity chromatography, allowing co-elution of isotopically labelled peptides for further analysis.²³⁶ However, screening of larger number of variable conditions was not possible.²³⁷ In 2002, isobaric tags were introduced, iTRAQ (Isobaric Tags for Relative and Absolute Quantitation)²³⁸ and tandem mass tags (TMT)^{239,240} as powerful tools for multiplexed MS proteomic analysis. These tags contain multiple isotopic variants that are chemically identical, and co-migrate in liquid chromatography separations but offer different MS signatures.

Optimisation of MS reporter peptides led to the design of a generation of reporters that used isobaric and non-isobaric isotope mass tagging for targeting proteases overexpressed in disease. The reporters generally contained a specific peptide-based substrate covalently linked to a MS tag. The tag-containing peptides co-eluted in chromatographic separations, while the combination of reporter peptides could be analysed by MS/MS. Findeisen developed a series of synthetic MS tagged reporter peptides^{25,241,242} to help address a key challenge of protease profiling in complex biological samples, namely the risk of cleavage by non-specific peptidases, that are generally very abundant in complex samples. This was achieved by incorporating a flanking aminohexanoic acid groups in the peptide substrate that successfully reduced degradation by native exopeptidases.²⁴²

Ouyang developed non-isotopic labels to screen for caspase-3 cleavable peptides,²⁴³ using MALDI-MS as the analytical method with peptides labelled by virtue of a terminal maleimide handle. This demonstrated sensitive detection of caspase-3 activity and offers a platform that would be applicable to other proteases.

Bhatia²⁴⁴ developed a variety of synthetic biomarkers for disease-related proteases based on photocaged tandem isobaric peptides allowing up to 10-plexed protease analysis in a single run for possible disease stratification (Fig. 25). The probes/reporters consisted of nanocluster carriers, conjugated to cleavable peptide mass reporters for proteases overexpressed in a variety of diseases. The reporters contained substrate peptides with isobaric MS tags conjugated through a photolabile linker²⁴⁵ with an additional peptide that enhances renal clearance. The nanocluster constructs were cleaved by disease related proteases and since the released fragments were connected to isobaric MS tags (*via* a photocleavable linker), this allowed comparative relative abundance quantification of all 10



Scheme 9 MS proteolytic profiling, where protease peptide substrates are modified with MS tags (shown here in blue, red or green) and used as reporters. Complex samples can be spiked with these mixtures of reporters and the targeted proteases cleave the peptides releasing the MS tags. Each tag has a unique MS spectrum and each reports on the activity of a different protease.



Table 2 MS-based methods for protease profiling

Strategy	Reporter peptide	Type of tag	Tag	Systems/ conditions	Protease	Ref.
Unlabelled peptide	Exogenous peptide from bacteria	Non-isotopic	Tryptic digest of the N-terminal adenomatous polyposis coli protein	2	Non-specific	Findeisen 2008 ²³³
MS encoded peptide	Synthetic protease substrate with protease resistant label	Non-isotopic	AhxAhx-HHHHHH	2	Cysteine-endopeptidase cancer procoagulant	Peccerella 2010 ²⁴¹
			Ahx-ateevlkl	2	Cysteine-endopeptidase cancer procoagulant	Yepes 2011 ²⁴²
			Dual maleimide (DuMal)	2	Caspase-3	Ouyoung 2012 ²⁵
Isobaric tagged peptides (iCore)	Isobaric	One letter code	d-Amino acids lowercase Note: Charges in the structures below refer to isotope mass additions not formal charges e ⁺³ G ⁺⁶ VndneeGFfsAr e ⁺² G ⁺⁶ Vndnee ⁺¹ GFfsAr e ⁺¹ G ⁺⁶ Vndnee ⁺² GFfsAr eG ⁺⁶ Vndnee ⁺² GFfs ⁺¹ Ar eG ⁺⁵ VndneeGFfs ⁺⁴ Ar e ⁺³ G ⁺¹ Vndnee ⁺¹ GFfs ⁺⁴ Ar e ⁺³ GVndneeG ⁺⁶ FfsAr e ⁺² GVndneeG ⁺⁶ Ffs ⁺¹ Ar e ⁺¹ GVndnee ⁺² G ⁺⁶ FfsAr eGVndnee ⁺³ G ⁺⁶ FfsAr	10	Thrombin Tissue factor FXa Cathepsin B MMP2 MMP7 MMP8 MMP9 MMP14	Bathia 2020 ²⁴⁴




Fig. 25 Mass tagged nanocluster carriers, conjugated to cleavable peptide mass reporters for profiling of MMP protease activity overexpressed in a variety of diseases.²⁴⁴ The nanoclusters (each containing a different peptide sequence) are delivered to the disease site where overexpressed proteases release the isobaric MS reporter tags that are filtered into the urine. The reporters in the urine are treated with light to release the MS isobaric tags that are analysed by MS/MS. NC: nanocluster

conditions/tags. One biomarker approach was developed for detection of fibrosis using so-called iron oxide nanoworms as carriers for the reporters,²⁴⁵ with each nanoworm containing multiple copies of the same isobaric peptide, with 10 different isobaric nanoworm complexes co-administered. Cleavage of the constructs led to reporters in urine, and an indication of active protease present. Following the same approach, probes were developed for the detection the protease activity in prostate²⁴⁶ and lung cancer.²⁴⁴

2.3 Electrochemical

Electrochemical probes are a class of chemical probes in which an electrode is used as a transducer element in the presence of an analyte that allows generation of an electrochemical signal

change. Electrochemical biosensors have been used for the last 60 years²⁴⁷ and were first reported was by Clark and Lyons²⁴⁸ to allow measurement of glucose levels. Based on their mode of operation and the type of electrode, electrochemical biosensors can be classified as potentiometric, amperometric or impedimetric but all have in common the conversion of chemical information into a measurable electrochemical signal.

Electrochemical protease biosensors offer some advantages over those based on fluorescence as they can offer higher specificity and sensitivity even in turbid or intrinsically fluorescent solutions. Many of these are also compatible with miniaturisation and mass-manufacture for point-of-care devices (Fig. 27).²⁴⁹ Comprehensive reviews covering this area include those by Vanova,²⁵⁰ Ming²⁴⁹ and Ong.¹⁶ Typically,



protease analysis probes are composed of a redox-tagged recognition peptide for the enzyme of interest, which is then attached to an electrode surface (Scheme 10). The flexibility of the peptide allows for the redox tag to come into contact with the electrode surface to elicit an electrochemical signal. Upon cleavage of the peptide by the enzyme of interest, the redox tag is released into the bulk solution and a quantifiable signal decrease can be used to determine enzyme activity. This was demonstrated by a probe (83) developed by Liu with ferrocene-labelled MMP-7-cleavable peptides immobilised onto a gold electrode.²⁵¹ In the absence of MMP-7, maximal voltammetric signal was achieved as the redox labels were close to the surface allowing redox cycling with the electrode surface. Observable decreases in the signal corresponded to various levels of MMP-7 in solution with a limit of detection of 0.1 ng mL^{-1} . *p*-Aminodiphenylamine (pADA) and methylene blue have been used as redox reporters in probes for thrombin (84)²⁵² and MMP-9 (85),²⁵³ and similar approaches have been employed for a range of other proteases including the cathepsin family,²⁵⁴ neutrophil elastase (87, Fig. 26)²⁵⁵ and HIV-1 protease (88).²⁵⁶ Gold electrodes have been always the classical choice when designing electrochemical protease probes, however, in recent years, several novel electrode platforms have been used showing excellent performance on protease sensing. Indium Tin Oxide electrodes²⁵⁷ and carbon based electrodes are examples of alternatives to gold electrodes used in the field. Embedded vertical carbon nanofiber electrodes, separated from each other forming a bush-like platform, were used for the detection of Cathepsin B (86).²⁵⁸ These approaches reduce steric hindrance





Fig. 26 Electrochemical detection of HNE (87).²⁵⁵ (a) % signal change-time course for substrate-modified electrodes immersed in varying HNE concentrations (0, 10, 50, 75, 100 and 150 nM) in HEPES buffer. (b) Adjusted signal, A (%), after 90 min plotted against the concentration of HNE. (c) Electrical signal registered at different incubation times (0, 5, 10, 20, 60 and 90 min) for 100 nM HNE in HEPES buffer. Reproduced from ref. 255 with permission Elsevier, copyright 2018.

and improve temporal resolution. Novel Pt based microelectrodes for detection of trypsin were pioneered by Ucar,²⁵⁹ whose results demonstrate similar specificity when compared to Au electrodes and enhanced reproducibility and stability. However, all these strategies rely on a ‘signal-off’ output, which may be undesirable.

A label-free strategy can be employed to overcome these drawbacks, wherein a peptide sequence is used to preclude or promote the approach of a redox mediator to the electrode surface; either by steric or electrostatic repulsion. An advantage of this strategy is that peptide substrates can be used without the need of a label, allowing for more sensitive assays. Cao has demonstrated a general method using electrostatic repulsion in a system where a peptide with a cationic region is immobilised on the electrode. The peptide formed a layer that prevents the penetration of the cationic $[\text{Ru}(\text{NH}_3)_6\text{Cl}_2]^+$ redox reporter due to electrostatic repulsion, and no electrical signal was transferred. Upon the cleavage of the peptide, the positively charged region was released and the reporter can approach the electrode surface to produce a ‘signal-on’ (89).²⁶⁰ However, this signal requires the addition of an electrochemical reporter to the assay. Deng designed a ‘signal off’ probe, using $[\text{Fe}(\text{CN})_6]^{3-/-4-}$ as a redox reporter and a peptide immobilised to a gold surface. A positively charged Lys in a peptide induced binding of the negatively charged redox reporter resulting in an electrical signal output. Upon the addition of the serine protease PSA, the Lys residue was cleaved and the reporter no longer binds the peptide, resulting in a decrease in the electrical signal.²⁶¹ However, high background-to-signal ratios limit the sensitivity of this method compared to redox labelled-peptide strategies.

Li,²⁶² using a gold electrode with immobilised peptides (*via* 11-mercaptopoundecanoic acid) developed a system that contained a ‘seed peptide’ that accelerates/catalyses amyloid β misfolding on the electrode surface. The incorporation of a cleavable sequence between the anchoring fragment and the



Scheme 10 Electrochemical sensing strategies for proteases. (a) Signal-off detection. Cleavage by the protease, releases the reporter from the electrode resulting in a decrease of signal. (b) Signal-on detection. Cleavage by the peptide demasks a high-affinity sequence that promotes electrochemical reporter binding, resulting in an increase in the electrochemical signal.



seed sequence allowed protease mediated release of the seed motif (and prevention of amyloid formation) allowing the electrode surface to be available for interactions with the free redox reporter.

Another example that falls in between a redox-labelled and label-free design is the 'signal on' system designed by Ko,²⁶³ based on the triggerable interaction of a redox reporter with the electrode. The system was used to report on the presence of thrombin using ferrocene as the redox reporter and a fibrinogen coated electrode. The electrode, coated with Fc-fibrinogen, was susceptible to thrombin mediated hydrolysis of the coating fibrinogen, that "demasked" the surface of the support.

Other strategies that depend on a complex formation or secondary triggered reactions have also been developed. Thus, proteolytic activity has been measured electrochemically by use of the cleaved peptide acting as a ligand for an electrocatalyst: for example, an electrocatalytic reaction can be triggered by caspase-3.²⁶⁴ Cleavage of the substrate peptide (**90**) released a Cu(II)/Ni(II) peptide binding motif (Ser-Lys-His) that resulted in the *in situ* synthesis of the reporter, a copper electrocatalyst for water oxidation at the electrode surface. The use of water as a substrate negates the need for addition of other reagents and provides a straightforward and simple operating procedure with low background current for caspase-3, and a LoD of 0.2 pg mL⁻¹. This sensing platform was shown to be robust




Fig. 27 Electrochemical probes for proteases where the signal increases upon protease activation. Abbreviations: pADA: *p*-aminodiphenylamine; Sta: statin (4-amino-3-hydroxy-6-methylheptanoic acid); Bt: biotin; arrows indicate cleavage site. While peptide sequences are always written N → C terminal by convention (NPeptideC), we have utilised some C → N (cPeptideN) to allow ease of presentation. *Binding based assay. Abbreviations: pADA: *p*-aminodiphenylamine; Sta: statin (4-amino-3-hydroxy-6-methylheptanoic acid); Bt: biotin; arrows indicate cleavage sites.




Fig. 27 (cont.)

in complex media, such as cell lysate. Following a similar principle, Wu²⁶⁵ developed a two-enzyme system (91) where the catalyst in this case was alkaline phosphatase (ALP) and the activating protease *B.lichenifromis*. ALP catalyses the formation of electrochemically active phenol. The system incorporated streptavidin-alkaline phosphatase (Sav-ALP) on the electrodes through a biotin-labelled peptide substrate. In absence of the protease, streptavidin-alkaline phosphatase catalyses the formation of a redox reporter, while in its presence the biotin moiety was removed from the electrodes reducing the electrochemical signal.

Chen²⁶⁶ reported a system with a LoD for caspase-3 of 0.06 pg mL^{-1} ($\sim 3 \text{ fM}$). The system used the triggerable binding of methylene blue to the electrode by immobilisation of a peptide substrate. Thus, an acetylated caspase-3 peptide substrate was anchored into an electrode *via* a C-terminal Cys residue (94). Cleavage exposed a free terminal amine group on the remaining anchored fragment, which was able to covalently bind graphene oxide. Electroactive methylene blue then bound through $\pi-\pi$ stacking and resulted in an increase of electrochemical signal. Meng²⁶⁷ used graphene oxide for the *in situ* generation of silver nanoparticles on a peptide functionalised

gold electrode. In the absence of PSA, the graphene oxide was immobilised on the peptide and silver nanoparticles were generated *in situ*, resulting in an electrochemical signal.

Xia used an immobilised peptide–heme catalyst complex²⁶⁸ to increase electrochemical signals in response to the β -amyloid precursor protein enzyme 1 (BACE1). The construct (93) consisted of a heme-binding segment ($\text{A}\beta_1 \rightarrow 16$), the heme being capable of the electrocatalytic reduction of O_2 . This sequence was bound to the BACE1 substrate whose cleavage by BACE1 released the heme binding region of the peptide, such that reduction of O_2 was no longer possible.

Attempts have been made to incorporate amplification within these systems to further increase their sensitivity. Magnetic beads or nanoparticles²⁶⁹ functionalised with peptide-reporter systems (94), have been used to assay activity in complex media (*e.g.* blood or urine) and can then be extracted and deposited onto magnetic electrodes, to allow analysis in less complex media (*e.g.* aqueous buffers). Neutravidin coated magnetic beads (95) were used for detection of trypsin²⁷⁰ with enhanced sensitivity and robustness in cell lysate and clinical samples (probe consisting of neutravidin magnetic nanoparticles functionalised with substrate peptides *via* a biotin moiety, labelled with a FITC antigen tag detectable by a labelled antibody). In the absence of trypsin, the peptide probe was intact and a high number of redox tags providing a large amperometric response (using the hydroquinone (HQ)/HRP/ H_2O_2 system). While the presence of trypsin decreased the amperometric signals. Fluorescence from cadmium telluride quantum dots (CdTe-QDs) was converted into measurable photocurrent by Liu,²⁷¹ using electrodes functionalised with a peptide that contained a positively charged region to attract the QDs (96). Upon trypsin cleavage, the QDs were released from the surface and the signal decreased.

A related strategy was designed by Yuan to translate the peptide cleavage event to a nucleic acid-based detection platform.²⁷² Peptide-functionalised magnetic polystyrene microspheres were coupled to DNA–AuNPs (97). The proteolytic action of the enzyme of interest (MMP-2) decouples the DNA–AuNPs from the peptide-microspheres with the DNA released by proteolytic activity hybridising to a redox-labelled complementary strand of DNA. Next, an exonuclease III assisted cycling signal amplification step was applied, whereby the duplex DNA was selectively digested to release the redox label (methylene blue), as well as the DNA–AuNP. The electrode surface, functionalised with a macrocyclic cavity (cucurbituril) binds the redox label and provides an electrical signal. The release of the DNA–AuNPs allows for another hybridisation event to occur with cyclical amplification system allowing a single DNA–AuNP to allow multiple redox labels to approach the electrode surface. The host–guest interactions at the electrode surface provided a LoD of 0.15 pg mL^{-1} . This ‘signal-on’ sensing platform allows for robust analysis, with multiple steps preventing false positive results and could be applied to a range of proteases in human serum.

Another method for amplification has been developed by Hu²⁷³ that combined the use of substrate peptides as a

recognition element and RAFT polymerization for signal amplification. Thrombin substrate peptides were immobilised onto a gold electrode *via* an N-terminal cysteine residue (98). Following cleavage by thrombin, the electrode was immersed into a solution containing a Zr(IV) source and a carboxylate-containing RAFT initiator. Only at the site of the cleaved peptide (free carboxylic acid), did the Zr complex form a bridge between the carboxylate of the RAFT initiator and the peptide. The addition of acrylate-ferrocene allowed polymerisation and recruitment of multiple redox reporters at the site of cleavage, allowing for very sensitive detection.

3 Summary and perspectives

In this review, we have discussed the recent advances, and highlighted the most relevant and novel substrate-based reporters and strategies, for the detection of proteolytic activity.

The design of substrate-based reporters for the detection of proteolytic activity needs to overcome a number of challenges, namely the level of sensitivity can be a challenge when trying to target relevant proteases where expression levels can be low; while specificity is another key issue. This means that the generation of highly specific probes to target a single protease within a relatively broad family (*e.g.* caspases or MMPs), becomes a difficult task due to overlap in substrate recognition, while by-stander cleavage by generic/non-specific proteases is a common problem. Most of the reporters described in this review, target model proteases that are well understood and have been extensively used in a variety of applications, but the targeting of novel, low abundance, protease biomarkers remains a challenge.

A key challenge in the area of optical probes remains their *in vivo* application, due to poor tissue penetration of light enabled by current imaging technologies and high background signals from complex biological environments. However, several reporters for proteolytic activity have entered clinical studies *e.g.* for margin detection during surgery, in the last decade. New strategies are driving improvements in tissue penetration and background signal reduction with the shifting of the emission of fluorescent probes into the near-infrared region and beyond.

Photoacoustic imaging allows for enhanced tissue penetration and can be used in combination with fluorescence, reaping the benefits of both worlds. Chemiluminogens show great promise as alternatives to fluorescence, with virtually no background signal, with efforts focused on improvement of probe stability and shifting of emission wavelength by tuning natural substrates. Quantitative analysis is not easily achieved with optical substrate-based probes and only a few examples exist that allows quantitative analysis in association with signal amplification. Activity-based probes, that covalently bind to the protease following activation, can overcome this problem, however, they render the protease inactive and provide no signal amplification. There has been much work in the area of theragnostics, with multimodal probes combining optical



imaging-based diagnosis and therapeutic intent, using photodynamic, photothermal strategies and activatable prodrugs.

On the *in vitro*-based application side, the novel applications of colorimetric sensing and electrochemical sensors offer great promise as low-cost and highly sensitive chemistries for point-of-care testing, but the immobilisation of the substrate probe can still present challenges. Electrochemical probes offer great promise as a point-of-care technology with the possibility of miniaturisation with relatively simple designs, however most rely on a signal-off response. MS based protease detection is a powerful tool for protease activity profiling, but a key challenge is the complexity of biological samples, that can affect the sensitivity/specificity of the assay and the resulting read-out.

The field of protease-based chemical probes is rapidly evolving to allow further detailed analysis of proteolytic events. In this review, we have described a few from the many examples of each type of probe applied in a variety of situations. The breadth of technologies developed enable access to protease detection in almost any situation, be it *in vivo* real-time fluorescent imaging by applying the concept of aggregation-induced emission or low-cost easily applied, colorimetric platforms for use in resource-limited settings. The future of protease chemical probes will continue to be bright, diverse and innovative.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We would like to thank the Engineering and Physical Sciences Research Council (EPSRC, UK) for Interdisciplinary Research Collaboration grant EP/R005257/1.

Notes and references

- 1 R. Visse and H. Nagase, *Circ. Res.*, 2003, **92**, 827–839.
- 2 S. Gottesman and M. R. Maurizi, *Microbiol. Rev.*, 1992, **56**, 592–621.
- 3 N. A. Thornberry and Y. Lazebnik, *Science*, 1998, **281**, 1312–1316.
- 4 J. E. Koblinska, M. Ahrama and B. F. Sloane, *Clin. Chim. Acta*, 2000, **291**, 113–135.
- 5 P. V. Ravindra and T. K. Girish, in *Proteases in Physiology and Pathology*, ed. S. Chakraborti and N. S. Dhalla, Springer Singapore, Singapore, 2017, DOI: 10.1007/978-981-10-2513-6-13, pp. 289–296.
- 6 C. E. Reed and H. Kita, *J. Allergy Clin. Immunol.*, 2004, **114**, 997–1008.
- 7 M. A. Slack and S. M. Gordon, *Arterioscler., Thromb., Vasc. Biol.*, 2019, **39**, e210–e218.
- 8 D. J. Selkoe and J. Hardy, *EMBO Mol. Med.*, 2016, **8**, 595–608.
- 9 M. S. Wolfe, M. Citron, T. S. Diehl, W. Xia, I. O. Donkor and D. J. Selkoe, *J. Med. Chem.*, 1998, **41**, 6–9.
- 10 Z. Lv, Y. Chu and Y. Wang, *HIV AIDS*, 2015, **7**, 95–104.
- 11 C. G. Smith and J. R. Vane, *FASEB J.*, 2003, 788–789.
- 12 M. Staderini, A. Megia-Fernandez, K. Dhaliwal and M. Bradley, *Bioorg. Med. Chem.*, 2018, **26**, 2816–2826.
- 13 L. E. Edgington, M. Verdoes and M. Bogyo, *Chem. Biol.*, 2011, **15**, 798–805.
- 14 J. Zhang, X. Chai, X. P. He, H. J. Kim, J. Yoon and H. Tian, *Chem. Soc. Rev.*, 2019, **48**, 683–722.
- 15 J. Chin and H. J. Kim, *Coord. Chem. Rev.*, 2018, **354**, 169–181.
- 16 I. L. H. Ong and K. L. Yang, *Analyst*, 2017, **142**, 1867–1881.
- 17 R. Oliveira-Silva, M. Sousa-Jeronimo, D. Botequim, N. J. O. Silva, P. M. R. Paulo and D. M. F. Prazeres, *Trends Biochem. Sci.*, 2020, **45**, 604–618.
- 18 T. Förster, *Ann. Phys.*, 1948, **437**, 55–75.
- 19 B. Wallace and P. J. Atzberger, *PLoS One*, 2017, **12**, e0177122.
- 20 T. W. Liu, J. Chen and G. Zheng, *Amino Acids*, 2011, **41**, 1123–1134.
- 21 J. J. Diaz-Mochon, L. Bialy, L. Keinicke and M. Bradley, *Chem. Commun.*, 2005, 1384–1386, DOI: 10.1039/b415847d.
- 22 P. M. S. Hilaire, M. Willert, M. A. Juliano, L. Juliano and M. Meldal, *J. Comb. Chem.*, 1999, **1**, 509–523.
- 23 C. Pinilla, J. Appel, S. Blondelle, C. Dooley, B. Dorner, J. Eichler, J. Ostresh and R. A. Hought, *Biopolymers*, 1995, **37**, 221–240.
- 24 P. Findeisen and M. Neumaier, *Proteomics Clin. Appl.*, 2012, **6**, 60–78.
- 25 D. Yepes, A. Jacob, M. Dauber, V. Costina, R. Hofheinz, M. Neumaier and P. Findeisen, *Int. J. Oncol.*, 2011, **39**, 145–154.
- 26 D. J. M. a. J. A. Wells, *Sci. Transl. Med.*, 1993, **260**, 1113–1117.
- 27 M. Tholen, J. J. Yim, K. Groborz, E. Yoo, B. A. Martin, N. S. van den Berg, M. Drag and M. Bogyo, *Angew. Chem., Int. Ed.*, 2020, **59**, 19143–19152.
- 28 M. Wartenberg, A. Saidi, M. Galibert, A. Joulin-Giet, J. Burlaud-Gaillard, F. Lecaille, C. J. Scott, V. Aucagne, A. F. Delmas and G. Lalmanach, *Biochimie*, 2019, **166**, 84–93.
- 29 P. Kasperkiewicz, M. Poreba, S. J. Snipas, S. J. Lin, D. Kirchhofer, G. S. Salvesen and M. Drag, *PLoS One*, 2015, **10**, e0132818.
- 30 A. Megia-Fernandez, B. Mills, C. Michels, S. V. Chankeshwara, K. Dhaliwal and M. Bradley, *Org. Biomol. Chem.*, 2017, **15**, 4344–4350.
- 31 S. Mathur, A. Turnbull, I. Akaev, C. Stevens, N. Agrawal, M. Chopra and D. Mincher, *Int. J. Pept. Res. Ther.*, 2019, **26**, 1965–1980.
- 32 H. A. Alhadrami, A. M. Hassan, R. Chinnappan, H. Al-Hadrami, W. H. Abdulaal, E. I. Azhar and M. Zourob, *Mikrochim. Acta*, 2021, **188**, 137.
- 33 T. Janiszewski, S. Kolt, D. Kaiserman, S. J. Snipas, S. Li, J. Kulbacka, J. Saczko, N. Bovenschen, G. Salvesen,



M. Drăg, P. I. Bird and P. Kasperkiewicz, *J. Biol. Chem.*, 2020, **295**, 9567–9582.

34 J. J. Yim, S. Harmsen, K. Flisikowski, T. Flisikowska, H. Namkoong, M. Garland, N. S. van den Berg, J. G. Vilches-Moure, A. Schnieke, D. Saur, S. Glasl, D. Gorpas, A. Habtezion, V. Ntziachristos, C. H. Contag, S. S. Gambhir, M. Bogyo and S. Rogalla, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2008072118.

35 J. I. Scott, Q. Deng and M. Vendrell, *ACS Chem. Biol.*, 2021, **16**, 1304–1317.

36 T. Jiang, E. S. Olson, Q. T. Nguyen, M. Roy, P. A. Jennings and R. Y. Tsien, *Proc. Natl. Acad. Sci. U. S. A.*, 2004, **101**, 17867–17872.

37 Y. Cheng, L. Zhao, Y. Li and T. Xu, *Chem. Soc. Rev.*, 2011, **40**, 2673–2703.

38 L. O. Ofori, N. P. Withana, T. R. Prestwood, M. Verdoes, J. J. Brady, M. M. Winslow, J. Sorger and M. Bogyo, *ACS Chem. Biol.*, 2015, **10**, 1977–1988.

39 E. Walker, Y. Liu, I. Kim, M. Biro, S. R. Iyer, H. Ezaldein, J. Scott, M. Merati, R. Mistur, B. Zhou, B. Straight, J. J. Yim, M. Bogyo, M. Mann, D. L. Wilson, J. P. Basilion and D. L. Popkin, *Cancer Res.*, 2020, **80**, 2045–2055.

40 M. J. Whitley, D. M. Cardona, A. L. Lazarides, I. Spasojevic, J. M. Ferrer, J. Cahill, C.-L. Lee, M. Snuderl, D. G. Blazer, E. S. Hwang, R. A. Greenup, P. J. Mosca, J. K. Mito, K. C. Cuneo, N. A. Larrier, E. K. O'Reilly, R. F. Riedel, W. C. Eward, D. B. Strasfeld, D. Fukumura, R. K. Jain, W. D. Lee, L. G. Griffith, M. G. Bawendi, D. G. Kirsch and B. E. Brigman, *Sci. Transl. Med.*, 2016, **8**, 320ra324.

41 B. L. Smith, C. R. Lanahan, M. C. Specht, B. N. Kelly, C. Brown, D. B. Strasfeld, J. M. Ferrer, U. Rai, R. Tang, T. Rice-Stitt, A. Biernacka, E. F. Brachtel and M. A. Gadd, *Ann. Surg. Oncol.*, 2020, **27**, 1854–1861.

42 B. L. Smith, M. A. Gadd, C. R. Lanahan, U. Rai, R. Tang, T. Rice-Stitt, A. L. Merrill, D. B. Strasfeld, J. M. Ferrer, E. F. Brachtel and M. C. Specht, *Breast Cancer Res. Treat.*, 2018, **171**, 413–420.

43 C. R. Lanahan, B. N. Kelly, M. A. Gadd, M. C. Specht, C. L. Brown, K. S. Hughes, R. Tang, U. Rai, E. F. Brachtel, T. Rice-Stitt and B. L. Smith, *Breast Cancer Res. Treat.*, 2021, **187**, 145–153.

44 R. Weissleder, C.-H. Tung, U. Mahmood and A. B. Jr, *Nat. Biotechnol.*, 1999, **17**, 375–378.

45 A. Megia-Fernandez, A. Marshall, A. R. Akram, B. Mills, S. V. Chankeshwara, E. Scholefield, A. Miele, B. C. McGorum, C. Michaels, N. Knighton, T. Vercauteren, F. Lacombe, V. Dentan, A. M. Bruce, J. Mair, R. Hitchcock, N. Hirani, C. Haslett, M. Bradley and K. Dhaliwal, *BME Front.*, 2021, **2021**, 1–11.

46 B. Mills, D. Norberg, K. Dhaliwal, A. R. Akram, M. Bradley and A. Megia-Fernandez, *Chem. Commun.*, 2020, **56**, 9962–9965.

47 M. Zhou, J. Hu, M. Zheng, Q. Song, J. Li and Y. Zhang, *Chem. Commun.*, 2016, **52**, 2342–2345.

48 H. Yan, L. He, W. Zhao, J. Li, Y. Xiao, R. Yang and W. Tan, *Anal. Chem.*, 2014, **86**, 11440–11450.

49 T. H. Craven, N. Avlonitis, N. McDonald, T. Walton, E. Scholefield, A. R. Akram, T. S. Walsh, C. Haslett, M. Bradley and K. Dhaliwal, *Sci. Rep.*, 2018, **8**, 13490.

50 N. Avlonitis, M. Debuinne, T. Aslam, N. McDonald, C. Haslett, K. Dhaliwal and M. Bradley, *Org. Biomol. Chem.*, 2013, **11**, 4414–4418.

51 S. Lebreton, S. E. How, M. Buchholz, B. E. Yingyongnarongkul and M. Bradley, *Tetrahedron*, 2003, **59**, 3945–3953.

52 Y. Zhang, M. Ucuncu, A. Gambardella, A. Baibek, J. Geng, S. Zhang, J. Clavadetscher, I. Litzen, M. Bradley and A. Lilienkampf, *J. Am. Chem. Soc.*, 2020, **142**(52), 21615–21621.

53 A. K. Galande, S. A. Hilderbrand, R. Weissleder and C.-H. Tung, *J. Med. Chem.*, 2006, **49**, 4715–4720.

54 J. M. Ellard, T. Zollitsch, W. J. Cummins, A. L. Hamilton and M. Bradley, *Angew. Chem., Int. Ed.*, 2002, **41**, 3233–3236.

55 V. Brinkmann, C. Goosmann, B. Fauler, Y. Uhelmann, D. S. Weiss, Y. Weinrauch and A. Zichlinsky, *Science*, 2004, **303**, 1532–1535.

56 M. R. Rios, G. Garoffolo, G. Rinaldi, A. Megia-Fernandez, S. Ferrari, C. T. Robb, A. G. Rossi, M. Pesce and M. Bradley, *Chem. Commun.*, 2020, **57**, 97–100.

57 K. Nagai, T. Sato and C. Kojima, *Bioorg. Med. Chem. Lett.*, 2021, **33**, 127726.

58 B. Brennecke, Q. Wang, W. Haap, U. Grether, H. Y. Hu and M. Nazare, *Bioconjugate Chem.*, 2021, **32**, 702–712.

59 Q. D. Mac, D. V. Mathews, J. A. Kahla, C. M. Stoffers, O. M. Delmas, B. A. Holt, A. B. Adams and G. A. Kwong, *Nat. Biomed. Eng.*, 2019, **3**, 281–291.

60 E. J. Kwon, J. S. Dudani and S. N. Bhatia, *Nat. Biomed. Eng.*, 2017, **1**, 1–10.

61 S. Y. Li, L. H. Liu, H. Cheng, B. Li, W. X. Qiu and X. Z. Zhang, *Chem. Commun.*, 2015, **51**, 14520–14523.

62 J. Xu, L. Fang, M. Shi, Y. Huang, L. Yao, S. Zhao, L. Zhang and H. Liang, *Chem. Commun.*, 2019, **55**, 1651–1654.

63 F. Li, Y. Chen, R. Lin, C. Miao, J. Ye, Q. Cai, Z. Huang, Y. Zheng, X. Lin, Z. Zheng and S. Weng, *Anal. Chim. Acta*, 2021, **1148**, 338201.

64 A. Megia-Fernandez, B. Mills, C. Michels, S. V. Chankeshwara, N. Krstajic, C. Haslett, K. Dhaliwal and M. Bradley, *Org. Biomol. Chem.*, 2018, **16**, 8056–8063.

65 J. C. Widen, M. Tholen, J. J. Yim, A. Antaris, K. M. Casey, S. Rogalla, A. Klaassen, J. Sorger and M. Bogyo, *Nat. Biomed. Eng.*, 2021, **5**, 264–277.

66 S.-Y. Li, L.-H. Liu, L. Rong, W.-X. Qiu, H.-Z. Jia, B. Li, F. Li and X.-Z. Zhang, *Adv. Funct. Mater.*, 2015, **25**, 7317–7326.

67 F. Liu, M. Yang, W. Song, X. Luo, R. Tang, Z. Duan, W. Kang, S. Xie, Q. Liu, C. Lei, Y. Huang, Z. Nie and S. Yao, *Chem. Sci.*, 2020, **11**, 2993–2998.

68 R. R. Jetson and C. J. Krusemark, *Angew. Chem., Int. Ed.*, 2016, **55**, 9562–9566.

69 R. Lee, S.-J. Choi, K. C. Moon, J. W. Park, K. Kim, S.-Y. Yoon and I. Youn, *ACS Biomater. Sci. Eng.*, 2019, **5**, 3039–3048.

70 S. Gehrig, M. A. Mall and C. Schultz, *Angew. Chem., Int. Ed.*, 2012, **51**, 6258–6261.



71 M. Guerra, V. S. Halls, J. Schatterny, M. Hagner, M. A. Mall and C. Schultz, *J. Am. Chem. Soc.*, 2020, **142**, 20299–20305.

72 M. Whitney, E. N. Savariar, B. Friedman, R. A. Levin, J. L. Crisp, H. L. Glasgow, R. Lefkowitz, S. R. Adams, P. Steinbach, N. Nishi, Q. T. Nguyen and R. Y. Tsien, *Angew. Chem., Int. Ed.*, 2013, **52**, 325–330.

73 M. Miampamba, J. Liu, A. Harootunian, A. J. Gale, S. Baird, S. L. Chen, Q. T. Nguyen, R. Y. Tsien and J. E. Gonzalez, *Theranostics*, 2017, **7**, 3369–3386.

74 L. Ge, Z. Liu and Y. Tian, *Chem. Sci.*, 2020, **11**, 2215–2224.

75 H. Lee, S. J. Kim, H. Shin and Y. P. Kim, *ACS Sens.*, 2020, **5**, 655–664.

76 C. Schulenburg, G. Faccio, D. Jankowska, K. Maniura-Weber and M. Richter, *Analyst*, 2016, **141**, 1645–1648.

77 Y. Okorochenkova, M. Porubsky, S. Benicka and J. Hlavac, *Chem. Commun.*, 2018, **54**, 7589–7592.

78 L. Chen, W. Sun, W. Li, J. Li, L. Du, W. Xu, H. Fang and M. Li, *Anal. Methods*, 2012, **4**, 2661–2663.

79 L. W. Zou, P. Wang, X. K. Qian, L. Feng, Y. Yu, D. D. Wang, Q. Jin, J. Hou, Z. H. Liu, G. B. Ge and L. Yang, *Biosens. Bioelectron.*, 2017, **90**, 283–289.

80 X. He, Y. Xu, W. Shi and H. Ma, *Anal. Chem.*, 2017, **89**, 3217–3221.

81 Z. Yang, W. Xu, J. Wang, L. Liu, Y. Chu, Y. Wang, Y. Hu, T. Yi and J. Hua, *J. Mater. Chem. C*, 2020, **8**, 8183–8190.

82 X. Huang, J. Song, B. C. Yung, X. Huang, Y. Xiong and X. Chen, *Chem. Soc. Rev.*, 2018, **47**, 2873–2920.

83 K. Du, L. Sheng, X. Luo, G. Fan, D. Shen, C. Wu and R. Shen, *Spectrochim. Acta, Part A*, 2021, **249**, 119328.

84 T. Cao, Z. Teng, L. Zheng, J. Qian, H. Ma, J. Wang, W. Qin and H. Guo, *Anal. Chim. Acta*, 2020, **1127**, 295–302.

85 T. Ma, Y. Hou, J. Zeng, C. Liu, P. Zhang, L. Jing, D. Shangguan and M. Gao, *J. Am. Chem. Soc.*, 2018, **140**, 211–218.

86 Y. Hou, J. Zhou, Z. Gao, X. Sun, C. Liu, D. Shangguan, W. Yang and M. Gao, *ACS Nano*, 2015, **9**, 3199–3205.

87 S. Y. Liu, A. M. Yan, W. Y. Guo, Y. Y. Fang, Q. J. Dong, R. R. Li, S. N. Ni, Y. Sun, W. C. Yang and G. F. Yang, *ACS Nano*, 2020, **14**, 4244–4254.

88 M. Wu and W. R. Algar, *Anal. Chem.*, 2015, **87**, 8078–8083.

89 W. R. Algar, A. Khachatrian, J. S. Melinger, A. L. Huston, M. H. Stewart, K. Susumu, J. B. Blanco-Canosa, E. Oh, P. E. Dawson and I. L. Medintz, *J. Am. Chem. Soc.*, 2017, **139**, 363–372.

90 H. Bui, C. W. Brown, 3rd, S. Buckhout-White, S. A. Diaz, M. H. Stewart, K. Susumu, E. Oh, M. G. Ancona, E. R. Goldman and I. L. Medintz, *Small*, 2019, **15**, 1805384.

91 J. Breidenbach, U. Bartz and M. Gutschow, *Biochim. Biophys. Acta, Proteins Proteomics*, 2020, **1868**, 140445.

92 M. Zimmerman, B. Ashe, E. C. Yurewicz and G. Patel, *Anal. Biochem.*, 1977, **78**, 47–51.

93 H. Chen, X. He, M. Su, W. Zhai, H. Zhang and C. Li, *J. Am. Chem. Soc.*, 2017, **139**, 10157–10163.

94 S. He, J. Li, Y. Lyu, J. Huang and K. Pu, *J. Am. Chem. Soc.*, 2020, **142**, 7075–7082.

95 Q. Gong, W. Shi, L. Li, X. Wu and H. Ma, *Anal. Chem.*, 2016, **88**, 8309–8314.

96 X. Guo, S. Mu, J. Li, Y. Zhang, X. Liu, H. Zhang and H. Gao, *J. Mater. Chem. B*, 2020, **8**, 767–775.

97 A. Ogasawara, M. Kamiya, K. Sakamoto, Y. Kuriki, K. Fujita, T. Komatsu, T. Ueno, K. Hanaoka, H. Onoyama, H. Abe, Y. Tsuji, M. Fujishiro, K. Koike, M. Fukayama, Y. Seto and Y. Urano, *Bioconjugate Chem.*, 2019, **30**, 1055–1060.

98 Q. Gong, L. Li, X. Wu and H. Ma, *Chem. Sci.*, 2016, **7**, 4694–4697.

99 X. He, L. Li, Y. Fang, W. Shi, X. Li and H. Ma, *Chem. Sci.*, 2017, **8**, 3479–3483.

100 X. He, Y. Hu, W. Shi, X. Li and H. Ma, *Chem. Commun.*, 2017, **53**, 9438–9441.

101 E. E. Mulvihill and D. J. Drucker, *Endocr. Rev.*, 2014, **35**, 992–1019.

102 A. P. Femia, L. Raimondi, G. Maglieri, M. Lodovici, E. Mannucci and G. Caderni, *Int. J. Cancer*, 2013, **133**, 2498–2503.

103 A. Beckenkamp, J. B. Willig, D. B. Santana, J. Nascimento, J. D. Paccez, L. F. Zerbini, A. N. Bruno, D. A. Pilger, M. R. Wink and A. Buffon, *PLoS One*, 2015, **10**, 1–17.

104 T. Liu, J. Ning, B. Wang, B. Dong, S. Li, X. Tian, Z. Yu, Y. Peng, C. Wang, X. Zhao, X. Huo, C. Sun, J. Cui, L. Feng and X. Ma, *Anal. Chem.*, 2018, **90**, 3965–3973.

105 H. Onoyama, M. Kamiya, Y. Kuriki, T. Komatsu, H. Abe, Y. Tsuji, K. Yagi, Y. Yamagata, S. Aikou, M. Nishida, K. Mori, H. Yamashita, M. Fujishiro, S. Nomura, N. Shimizu, M. Fukayama, K. Koike, Y. Urano and Y. Seto, *Sci. Rep.*, 2016, **6**, 26399.

106 T. Mizushima, S. Ohnishi, Y. Shimizu, Y. Hatanaka, K. C. Hatanaka, Y. Kuriki, M. Kamiya, A. Homma, K. Yamamoto, S. Ono, Y. Urano and N. Sakamoto, *Head Neck*, 2018, **40**, 1466–1475.

107 K. Yamamoto, S. Ohnishi, T. Mizushima, J. Kodaira, M. Ono, Y. Hatanaka, K. C. Hatanaka, Y. Kuriki, M. Kamiya, N. Ehira, K. Shinada, H. Takahashi, Y. Shimizu, Y. Urano and N. Sakamoto, *BMC Cancer*, 2020, **20**, 64.

108 Q. Gong, W. Shi, L. Li and H. Ma, *Chem. Sci.*, 2016, **7**, 788–792.

109 W. Zhang, F. Liu, C. Zhang, J. G. Luo, J. Luo, W. Yu and L. Kong, *Anal. Chem.*, 2017, **89**, 12319–12326.

110 M. Sakabe, D. Asanuma, M. Kamiya, R. J. Iwatake, K. Hanaoka, T. Terai, T. Nagano and Y. Urano, *J. Am. Chem. Soc.*, 2013, **135**, 409–414.

111 K. Yamamoto, M. Kamiya and Y. Urano, *Bioorg. Med. Chem. Lett.*, 2019, **29**, 126663.

112 S. Y. Liu, H. Xiong, R. R. Li, W. C. Yang and G. F. Yang, *Anal. Chem.*, 2019, **91**, 3877–3884.

113 Q. Sun, J. Li, W. N. Liu, Q. J. Dong, W. C. Yang and G. F. Yang, *Anal. Chem.*, 2013, **85**, 11304–11311.

114 S. Wang, B. G. Vigliarolo, M. A. Chowdhury, J. N. K. Nyarko, D. D. Mousseau and C. P. Phenix, *Bioorg. Chem.*, 2019, **92**, 103194.

115 Y. Wang, J. Li, L. Feng, J. Yu, Y. Zhang, D. Ye and H. Y. Chen, *Anal. Chem.*, 2016, **88**, 12403–12410.



116 Y. Urano, M. Sakabe, N. Kosaka, M. Ogawa, M. Mitsunaga, D. Asanuma, M. Kamiya, M. R. Young, T. Nagano, P. L. Choyke and H. Kobayashi, *Sci. Transl. Med.*, 2011, **3**, 110ra119.

117 R. Obara, M. Kamiya, Y. Tanaka, A. Abe, R. Kojima, T. Kawaguchi, M. Sugawara, A. Takahashi, T. Noda and Y. Urano, *Angew. Chem., Int. Ed.*, 2021, **60**, 2125–2129.

118 J. Luo, Z. Xie, J. W. Lam, L. Cheng, H. Chen, C. Qiu, H. S. Kwok, X. Zhan, Y. Liu, D. Zhu and B. Z. Tang, *Chem. Commun.*, 2001, 1740–1741, DOI: 10.1039/b105159h.

119 Y. Chen, J. W. Y. Lam, R. T. K. Kwok, B. Liu and B. Z. Tang, *Mater. Horiz.*, 2019, **6**, 428–433.

120 Y. Hong, *Methods Appl. Fluoresc.*, 2016, **4**, 022003.

121 M. Chen, L. Li, H. Nie, J. Tong, L. Yan, B. Xu, J. Z. Sun, W. Tian, Z. Zhao, A. Qin and B. Z. Tang, *Chem. Sci.*, 2015, **6**, 1932–1937.

122 H. Shi, R. T. Kwok, J. Liu, B. Xing, B. Z. Tang and B. Liu, *J. Am. Chem. Soc.*, 2012, **134**, 17972–17981.

123 Y. Yuan, C. J. Zhang, M. Gao, R. Zhang, B. Z. Tang and B. Liu, *Angew. Chem., Int. Ed.*, 2015, **54**, 1780–1786.

124 D. Ding, J. Liang, H. Shi, R. T. K. Kwok, M. Gao, G. Feng, Y. Yuan, B. Z. Tang and B. Liu, *J. Mater. Chem. B*, 2014, **2**, 231–238.

125 Y. Wang, X. Wu, Y. Cheng and X. Zhao, *Chem. Commun.*, 2016, **52**, 3478–3481.

126 S. Huang, Y. Wu, F. Zeng, J. Chen and S. Wu, *Anal. Chim. Acta*, 2018, **1031**, 169–177.

127 X. Liu and G. Liang, *Chem. Commun.*, 2017, **53**, 1037–1040.

128 T. I. Kim, H. Jin, J. Bae and Y. Kim, *Anal. Chem.*, 2017, **89**, 10565–10569.

129 J. Li, W. Y. Lee, T. Wu, C. W. Leung, J. Xu, D. S. Wong, R. Li, G. Li, B. Z. Tang and L. Bian, *Adv. Biosyst.*, 2018, **2**, 1800010.

130 Y. Yuan, C. J. Zhang, R. T. K. Kwok, D. Mao, B. Z. Tang and B. Liu, *Chem. Sci.*, 2017, **8**, 2723–2728.

131 H. Han, W. Teng, T. Chen, J. Zhao, Q. Jin, Z. Qin and J. Ji, *Chem. Commun.*, 2017, **53**, 9214–9217.

132 Y. Yuan, R. Zhang, X. Cheng, S. Xu and B. Liu, *Chem. Sci.*, 2016, **7**, 4245–4250.

133 Y. Yuan, C.-J. Zhang, R. T. K. Kwok, S. Xu, R. Zhang, J. Wu, B. Z. Tang and B. Liu, *Adv. Funct. Mater.*, 2015, **25**, 6586–6595.

134 Y. Yuan, R. T. Kwok, B. Z. Tang and B. Liu, *J. Am. Chem. Soc.*, 2014, **136**, 2546–2554.

135 Y. Cheng, F. Huang, X. Min, P. Gao, T. Zhang, X. Li, B. Liu, Y. Hong, X. Lou and F. Xia, *Anal. Chem.*, 2016, **88**, 8913–8919.

136 Y. Zhang, Y. Li, N. Yang, X. Yu, C. He, N. Niu, C. Zhang, H. Zhou, C. Yu and S. Jiang, *Sens. Actuators, B*, 2018, **257**, 1143–1149.

137 J. Kaur, J. N. Malegaonkar, S. V. Bhosale and P. K. Singh, *J. Mol. Liq.*, 2021, **333**, 115980.

138 H. Li, G. Parigi, C. Luchinat and T. J. Meade, *J. Am. Chem. Soc.*, 2019, **141**, 6224–6233.

139 E. M. Sletten and C. R. Bertozzi, *Acc. Chem. Res.*, 2011, **44**, 666–676.

140 J. A. Prescher, D. H. Dube and C. R. Bertozzi, *Nature*, 2004, **430**, 873–877.

141 P. Shieh and C. R. Bertozzi, *Org. Biomol. Chem.*, 2014, **12**, 9307–9320.

142 S. Debieu and A. Romieu, *Org. Biomol. Chem.*, 2017, **15**, 2575–2584.

143 S. Debieu and A. Romieu, *Tetrahedron Lett.*, 2018, **59**, 1940–1944.

144 R. Huo, X. Zheng, W. Liu, L. Zhang, J. Wu, F. Li, W. Zhang, C. S. Lee and P. Wang, *Chem. Commun.*, 2020, **56**, 10902–10905.

145 Q. Wu, K. Y. Zhang, P. Dai, H. Zhu, Y. Wang, L. Song, L. Wang, S. Liu, Q. Zhao and W. Huang, *J. Am. Chem. Soc.*, 2020, **142**, 1057–1064.

146 D. Ye, A. J. Shuhendler, L. Cui, L. Tong, S. S. Tee, G. Tikhomirov, D. W. Felsher and J. Rao, *Nat. Chem.*, 2014, **6**, 519–526.

147 V. S. Padalkar and S. Seki, *Chem. Soc. Rev.*, 2016, **45**, 169–202.

148 W. Liu, S. J. Liu, Y. Q. Kuang, F. Y. Luo and J. H. Jiang, *Anal. Chem.*, 2016, **88**, 7867–7872.

149 D. P. Nair, M. Podgórski, S. Chatani, T. Gong, W. Xi, C. R. Fenoli and C. N. Bowman, *Chem. Mater.*, 2013, **26**, 724–744.

150 X. Yang, Y. Guo and R. M. Strongin, *Angew. Chem., Int. Ed.*, 2011, **50**, 10690–10693.

151 G. Zomer, *Chemiluminescence and Bioluminescence*, 2010, DOI: 10.1039/9781849732024-00051, pp. 51–90.

152 A. Roda, M. Guardigli, P. Pasini, M. Mirasoli, E. Michelini and M. Musiani, *Anal. Chim. Acta*, 2005, **541**, 25–35.

153 Y. Yan, P. Shi, W. Song and S. Bi, *Theranostics*, 2019, **9**, 4047–4065.

154 N. Thorne, J. Inglese and D. S. Auld, *Chem. Biol.*, 2010, **17**, 646–657.

155 A. Fleiss and K. S. Sarkisyan, *Curr. Genet.*, 2019, **65**, 877–882.

156 N. Hananya and D. Shabat, *Angew. Chem., Int. Ed.*, 2017, **56**, 16454–16463.

157 A. P. Jathoul, H. Grounds, J. C. Anderson and M. A. Pule, *Angew. Chem., Int. Ed.*, 2014, **53**, 13059–13063.

158 S. Iwano, R. Obata, C. Miura, M. Kiyama, K. Hama, M. Nakamura, Y. Amano, S. Kojima, T. Hirano, S. Maki and H. Niwa, *Tetrahedron*, 2013, **69**, 3847–3856.

159 M. S. Evans, J. P. Chaurette, S. T. Adams, Jr., G. R. Reddy, M. A. Paley, N. Aronin, J. A. Prescher and S. C. Miller, *Nat. Methods*, 2014, **11**, 393–395.

160 T. Kuchimaru, S. Iwano, M. Kiyama, S. Mitsumata, T. Kadonosono, H. Niwa, S. Maki and S. Kizaka-Kondoh, *Nat. Commun.*, 2016, **7**, 11856.

161 R. Kojima, H. Takakura, T. Ozawa, Y. Tada, T. Nagano and Y. Urano, *Angew. Chem., Int. Ed.*, 2013, **52**, 1175–1179.

162 Y. Ni, Z. Hai, T. Zhang, Y. Wang, Y. Yang, S. Zhang and G. Liang, *Anal. Chem.*, 2019, **91**, 14834–14837.

163 T. Monsees, W. Miska and R. Geiger, *Anal. Biochem.*, 1994, **221**, 329–334.

164 W. Miska and R. Geiger, *J. Clin. Chem. Clin. Biochem.*, 1987, **25**, 23–30.



165 M. Kindermann, H. Roschitzki-Voser, D. Caglic, U. Repnik, C. Miniejew, P. R. Mittl, G. Kosec, M. G. Grutter, B. Turk and K. U. Wendt, *Chem. Biol.*, 2010, **17**, 999–1007.

166 A. Dragulescu-Andrasi, G. Liang and J. Rao, *Bioconjugate Chem.*, 2009, **20**, 1660–1666.

167 G. C. Van de Bittner, C. R. Bertozzi and C. J. Chang, *J. Am. Chem. Soc.*, 2013, **135**, 1783–1795.

168 S. Talley, O. Kalinina, M. Winek, W. Paik, A. R. Cannon, F. Alonso, 3rd, M. A. Choudhry, K. L. Knight and E. M. Campbell, *J. Immunol.*, 2019, **203**, 2497–2507.

169 J. G. Morin and J. W. Hastings, *J. Cell. Physiol.*, 1970, **77**, 313–318.

170 H. Dacres, M. Michie and S. C. Trowell, *Anal. Biochem.*, 2012, **424**, 206–210.

171 F. Weihs, M. Gel, J. Wang, A. Anderson, S. Trowell and H. Dacres, *Biosens. Bioelectron.*, 2020, **158**, 112162.

172 A. den Hamer, P. Dierickx, R. Arts, J. de Vries, L. Brunsved and M. Merkx, *ACS Sens.*, 2017, **2**, 729–734.

173 H. Dacres, J. Wangb, A. Andersonb and S. C. Trowellb, *Sens. Actuators, B*, 2019, **301**, 127141.

174 F. Weihs, A. Peh and H. Dacres, *Anal. Chim. Acta*, 2020, **1102**, 99–108.

175 A. P. Schaap, R. S. Handley and B. P. Gin, *Tetrahedron Lett.*, 1987, **28**, 935–938.

176 N. Hananya and D. Shabat, *ACS Cent. Sci.*, 2019, **5**, 949–959.

177 J. A. Richard, L. Jean, C. Schenkels, M. Massonneau, A. Romieu and P. Y. Renard, *Org. Biomol. Chem.*, 2009, **7**, 2941–2957.

178 J.-A. Richard, L. Jean, A. Romieu, M. Massonneau, P. Noack-Fraissignes and P.-Y. Renard, *Org. Lett.*, 2007, **9**, 4853–4855.

179 O. Green, T. Eilon, N. Hananya, S. Gutkin, C. R. Bauer and D. Shabat, *ACS Cent. Sci.*, 2017, **3**, 349–358.

180 M. E. Roth-Konforti, C. R. Bauer and D. Shabat, *Angew. Chem., Int. Ed.*, 2017, **56**, 15633–15638.

181 L. S. Ryan and A. R. Lippert, *Angew. Chem., Int. Ed.*, 2018, **57**, 622–624.

182 J. I. Scott, S. Gutkin, O. Green, E. J. Thompson, T. Kitamura, D. Shabat and M. Vendrell, *Angew. Chem., Int. Ed.*, 2021, **60**, 5699–5703.

183 B. M. Babin, G. Fernandez-Cuervo, J. Sheng, O. Green, A. A. Ordonez, M. L. Turner, L. J. Keller, S. K. Jain, D. Shabat and M. Bogyo, *ACS Cent. Sci.*, 2021, **7**, 803–814.

184 N. Hananya, J. P. Reid, O. Green, M. S. Sigman and D. Shabat, *Chem. Sci.*, 2019, **10**, 1380–1385.

185 S. Gutkin, O. Green, G. Raviv, D. Shabat and O. Portnoy, *Bioconjugate Chem.*, 2020, **31**, 2488–2493.

186 N. Hananya, A. Eldar Boock, C. R. Bauer, R. Satchi-Fainaro and D. Shabat, *J. Am. Chem. Soc.*, 2016, **138**, 13438–13446.

187 N. Hananya, O. Press, A. Das, A. Scomparin, R. Satchi-Fainaro, I. Sagi and D. Shabat, *Chemistry*, 2019, **25**, 14679–14687.

188 Q. Miao and K. Pu, *Bioconjugate Chem.*, 2016, **27**, 2808–2823.

189 Y. Zhang, H. Hong and W. Cai, *Cold Spring Harb. Protoc.*, 2011, DOI: 10.1101/pdb.top065508.

190 J. Weber, P. C. Beard and S. E. Bohndiek, *Nat. Methods*, 2016, **13**, 639–650.

191 Y. P. a. G. K. Xueding Wang, *Opt. Lett.*, 2003, **28**, 1739–1741.

192 J. T. Oh, M. L. Li, H. F. Zhang, K. Maslov, G. Stoica and L. V. Wang, *J. Biomed. Opt.*, 2006, **11**, 34032.

193 H. Wang, K. Xue, Z. Duan, Y. Yang, Z. He, C. Wu, W. Zhang, W. Zhang, P. Li and B. Tang, *Sens. Actuators, B*, 2019, **286**, 243–249.

194 P. Cheng, W. Chen, S. Li, S. He, Q. Miao and K. Pu, *Adv. Mater.*, 2020, **32**, e1908530.

195 L. Yin, H. Sun, M. Zhao, A. Wang, S. Qiu, Y. Gao, J. Ding, S. J. Ji, H. Shi and M. Gao, *J. Org. Chem.*, 2019, **84**, 6126–6133.

196 C. Lee, M. Jeon and C. Kim, *Applications of Nanoscience in Photomedicine*, 2015, DOI: 10.1533/9781908818782.31, pp. 31–47.

197 J. Weber, P. C. Beard and S. E. Bohndiek, *Nat. Methods*, 2016, **13**, 639–650.

198 K. Haedicke, C. Brand, M. Omar, V. Ntziachristos, T. Reiner and J. Grimm, *Photoacoustics*, 2017, **6**, 1–8.

199 B. M. Wallis de Vries, J. L. Hillebrands, G. M. van Dam, R. A. Tio, J. S. de Jong, R. H. Slart and C. J. Zeebregts, *Circulation*, 2009, **119**, e534–e536.

200 D. Razansky, N. J. Harlaar, J. L. Hillebrands, A. Taruttis, E. Herzog, C. J. Zeebregts, G. M. van Dam and V. Ntziachristos, *Mol. Imaging Biol.*, 2012, **14**, 277–285.

201 J. Levi, S. R. Kothapalli, T.-J. Ma, K. Hartman, B. T. Khuri-Yakub and S. S. Gambhir, *J. Am. Chem. Soc.*, 2010, **132**, 11264–11269.

202 Q. Li, S. Li, S. He, W. Chen, P. Cheng, Y. Zhang, Q. Miao and K. Pu, *Angew. Chem., Int. Ed.*, 2020, **59**, 7018–7023.

203 K. Yang, L. Zhu, L. Nie, X. Sun, L. Cheng, C. Wu, G. Niu, X. Chen and Z. Liu, *Theranostics*, 2014, **4**, 134–141.

204 C. Liu, S. Li, Y. Gu, H. Xiong, W. T. Wong and L. Sun, *Mol. Imaging Biol.*, 2018, **20**, 919–929.

205 L. Yin, H. Sun, H. Zhang, L. He, L. Qiu, J. Lin, H. Xia, Y. Zhang, S. Ji, H. Shi and M. Gao, *J. Am. Chem. Soc.*, 2019, **141**, 3265–3273.

206 D. Zhang, G. B. Qi, Y. X. Zhao, S. L. Qiao, C. Yang and H. Wang, *Adv. Mater.*, 2015, **27**, 6125–6130.

207 A. Dragulescu-Andrasi, S. R. Kothapalli, G. A. Tikhomirov, J. Rao and S. S. Gambhir, *J. Am. Chem. Soc.*, 2013, **135**, 11015–11022.

208 Y. Wang, X. Hu, J. Weng, J. Li, Q. Fan, Y. Zhang and D. Ye, *Angew. Chem., Int. Ed.*, 2019, **58**, 4886–4890.

209 A. Lakshmanan, Z. Jin, S. P. Nety, D. P. Sawyer, A. Lee-Gosselin, D. Malounda, M. B. Swift, D. Maresca and M. G. Shapiro, *Nat. Chem. Biol.*, 2020, **16**, 988–996.

210 F. Xia, J. Niu, Y. Hong, C. Li, W. Cao, L. Wang, W. Hou, Y. Liu and D. Cui, *Acta Biomater.*, 2019, **89**, 289–299.

211 S. Nakamura, T. Morita, S. Iwanaga, M. Miwa and K. Takahashi, *J. Biochem.*, 1977, **81**, 1567–1569.

212 X. Zhu and T. Gao, *Nano-Inspired Biosensors for Protein Assay with Clinical Applications*, 2019, DOI: 10.1016/b978-0-12-815053-5.00010-6, pp. 237–264.



213 H. Aldewachi, T. Chalati, M. N. Woodroffe, N. Bricklebank, B. Sharrack and P. Gardiner, *Nanoscale*, 2017, **10**, 18–33.

214 E. Petryayeva and U. J. Krull, *Anal. Chim. Acta*, 2011, **706**, 8–24.

215 Q. Zhang, Y. Lu, S. Li, J. Wu and Q. Liu, *Peptide Applications in Biomedicine, Biotechnology and Bioengineering*, 2018, DOI: 10.1016/b978-0-08-100736-5.00024-7, pp. 565–601.

216 P. Chen, R. Selegard, D. Aili and B. Liedberg, *Nanoscale*, 2013, **5**, 8973–8976.

217 Y. Pan, M. Guo, Z. Nie, Y. Huang, Y. Peng, A. Liu, M. Qing and S. Yao, *Chem. Commun.*, 2012, **48**, 997–999.

218 G. Chen, Y. Xie, H. Zhang, P. Wang, H.-Y. Cheung, M. Yang and H. Sun, *RSC Adv.*, 2014, **4**, 6560–6563.

219 W. Xue, G. Zhang and D. Zhang, *Analyst*, 2011, **136**, 3136–3141.

220 G. B. Kim, K. H. Kim, Y. H. Park, S. Ko and Y. P. Kim, *Biosens. Bioelectron.*, 2013, **41**, 833–839.

221 X. Ding, D. Ge and K.-L. Yang, *Sens. Actuators, B*, 2014, **201**, 234–239.

222 M. Q. He, S. Chen, K. Yao, J. Meng, K. Wang, Y. L. Yu and J. H. Wang, *Anal. Chem.*, 2020, **92**, 1395–1401.

223 N. Xia, D. Deng, Y. Wang, C. Fang and S. J. Li, *Int. J. Nanomed.*, 2018, **13**, 2521–2530.

224 L. Liu, D. Deng, Y. Wang, K. Song, Z. Shang, Q. Wang, N. Xia and B. Zhang, *Sens. Actuators, B*, 2018, **266**, 246–254.

225 C. N. Loynachan, A. P. Soleimany, J. S. Dudani, Y. Lin, A. Najar, A. Bekdemir, Q. Chen, S. N. Bhatia and M. M. Stevens, *Nat. Nanotechnol.*, 2019, **14**, 883–890.

226 G. A. Suaifan, C. Esseghaier, A. Ng and M. Zourob, *Analyst*, 2013, **138**, 3735–3739.

227 S. Wignarajah, G. A. Suaifan, S. Bizzarro, F. J. Bikker, W. E. Kaman and M. Zourob, *Anal. Chem.*, 2015, **87**, 12161–12168.

228 S. Alhogail, G. Suaifan and M. Zourob, *Biosens. Bioelectron.*, 2016, **86**, 1061–1066.

229 S. Alhogail, G. Suaifan, F. J. Bikker, W. E. Kaman, K. Weber, D. Cialla-May, J. Popp and M. M. Zourob, *ACS Omega*, 2019, **4**, 21684–21688.

230 R. I. Roth and J. Levin, *J. Biochem. Biophys. Methods*, 1989, **19**, 129–142.

231 D. Yang, H. J. Park and T. H. Yoo, *Anal. Methods*, 2016, **8**, 6270–6276.

232 Z. Ling, F. Xu, J. V. Edwards, N. T. Prevost, S. Nam, B. D. Condon and A. D. French, *Carbohydr. Polym.*, 2019, **216**, 360–368.

233 P. Findeisen, T. Peckerella, S. Post, F. Wenz and M. Neumaier, *Rapid Commun. Mass Spectrom.*, 2008, **22**, 1223–1229.

234 J.-L. Hsu, S.-Y. Huang, N.-H. Chow and S.-H. Chen, *Anal. Chem.*, 2003, **75**, 6843–6852.

235 S. P. Gygi, B. Rist, S. A. Gerber, F. Turecek, M. H. Gelb and R. Aebersold, *Nat. Biotechnol.*, 1999, **17**, 994–999.

236 T. J. Griffin, D. K. M. Han, S. P. Gygi, B. Rist, H. Lee and R. Aebersold, *J. Am. Soc. Mass Spectrom.*, 2001, **12**, 1238–1246.

237 R. Bachor, M. Waliczek, P. Stefanowicz and Z. Szewczuk, *Molecules*, 2019, **24**, 701.

238 K. Jia, X. Zhao and X. Dang, *Oncol. Lett.*, 2020, **19**, 4106–4114.

239 N. Rauniyar and J. R. Yates, 3rd, *J. Proteome Res.*, 2014, **13**, 5293–5309.

240 A. Thompson, J. Schafer, K. Kuhn, S. Kienle, J. Schwarz, G. Schmidt, T. Neumann and C. Hamon, *Anal. Chem.*, 2002, **75**, 1895–1904.

241 T. Peckerella, N. Lukan, R. Hofheinz, D. Schadendorf, M. Kostrezewa, M. Neumaier and P. Findeisen, *Clin. Chem.*, 2010, **56**, 272–280.

242 P. Findeisen, V. Costina, D. Yepes, R. Hofheinz and M. Neumaier, *J. Exp. Clin. Cancer Res.*, 2012, **31**, 56.

243 F. Ouyang, T. Yu, C. Gu, G. Wang, R. Shi, R. Lv, E. Wu, C. Ma, R. Guo, J. Li, A. Zaczek and J. Liu, *Analyst*, 2019, **144**, 6751–6759.

244 J. D. Kirkpatrick, A. D. Warren, A. P. Soleimany, P. M. K. Westcott, J. C. Voog, C. Martin-Alonso, H. E. Fleming, T. Tammela, T. Jacks and S. N. Bhatia, *Sci. Trans. Med.*, 2020, **12**, eaaw0262.

245 B. B. Brown, D. S. Wagner and H. M. Geysen, *Mol. Diversity*, 1995, **1**, 4–12.

246 J. S. Dudani, M. Ibrahim, J. Kirkpatrick, A. D. Warren and S. N. Bhatia, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**, 8954–8959.

247 M. Pohanka and P. Skládal, *J. Appl. Biomed.*, 2008, **6**, 57–64.

248 L. C. Clark, Jr. and C. Lyons, *Ann. N. Y. Acad. Sci.*, 1962, **102**, 29–45.

249 X.-Y. Z. Ming La, Q.-L. Peng, C.-D. Chen and G.-Q. Zhao, *Int. J. Electrochem. Sci.*, 2015, **10**, 3329–3339.

250 V. Vanova, K. Mitrevska, V. Milosavljevic, D. Hynek, L. Richtera and V. Adam, *Biosens. Bioelectron.*, 2021, **180**, 113087.

251 G. Liu, J. Wang, D. S. Wunschel and Y. Lin, *J. Am. Chem. Soc.*, 2006, **128**, 12382–12383.

252 J. Ji, J. Gan, J. Kong, P. Yang, B. Liu and C. Ji, *Electrochem. Commun.*, 2012, **16**, 53–56.

253 D. S. Shin, Y. Liu, Y. Gao, T. Kwa, Z. Matharu and A. Revzin, *Anal. Chem.*, 2013, **85**, 220–227.

254 L. Z. Swisher, A. M. Prior, S. Shishido, T. A. Nguyen, D. H. Hua and J. Li, *Biosens. Bioelectron.*, 2014, **56**, 129–136.

255 E. González-Fernández, M. Staderini, A. Yussof, E. Scholefield, A. F. Murray, A. R. Mount and M. Bradley, *Biosens. Bioelectron.*, 2018, **119**, 209–214.

256 K. Kerman, K. A. Mahmoud and H.-B. Kraatz, *Chem. Commun.*, 2007, 3829–3831.

257 J. Liu, H. Cheng, D. He, X. He, K. Wang, Q. Liu, S. Zhao and X. Yang, *Anal. Chem.*, 2017, **89**, 9062–9068.

258 Y. Song, H. Fan, M. J. Anderson, J. G. Wright, D. H. Hua, J. Koehne, M. Meyyappan and J. Li, *Anal. Chem.*, 2019, **91**, 3971–3979.

259 A. Ucar, E. Gonzalez-Fernandez, M. Staderini, N. Avlonitis, A. F. Murray, M. Bradley and A. R. Mount, *Analyst*, 2020, **145**, 975–982.

260 Y. Cao, J. Yu, B. Bo, Y. Shu and G. Li, *Biosens. Bioelectron.*, 2013, **45**, 1–5.



261 Y. S. Dehua Deng, H. Feng, Q. Chen, D. Li and L. Liu, *Int. J. Electrochem. Sci.*, 2013, **8**, 6933–6940.

262 H. Li, Y. Huang, B. Zhang, D. Yang, X. Zhu and G. Li, *Theranostics*, 2014, **4**, 701–707.

263 H. Ko, S. Park and K. Kim, *J. Electroanal. Chem.*, 2015, **742**, 70–73.

264 D. Deng, Y. Hao, S. Yang, Q. Han, L. Liu, Y. Xiang, F. Tu and N. Xia, *Sens. Actuators, B*, 2019, **286**, 415–420.

265 H. Wu, S. Liu, J. Jiang, G. Shen and R. Yu, *Analyst*, 2012, **137**, 4829–4833.

266 H. Chen, J. Zhang, Y. Gao, S. Liu, K. Koh, X. Zhu and Y. Yin, *Biosens. Bioelectron.*, 2015, **68**, 777–782.

267 F. Meng, H. Sun, Y. Huang, Y. Tang, Q. Chen and P. Miao, *Anal. Chim. Acta*, 2019, **1047**, 45–51.

268 N. Xia, Y. Zhang, P. Guan, Y. Hao and L. Liu, *Sens. Actuators, B*, 2015, **213**, 111–115.

269 X. Miao, H. Yu, Z. Gu, L. Yang, J. Teng, Y. Cao and J. Zhao, *Anal. Bioanal. Chem.*, 2017, **409**, 6723–6730.

270 C. Muñoz-San Martin, M. Pedrero, M. Gamella, A. Montero-Calle, R. Barderas, S. Campuzano and J. M. Pingarron, *Anal. Bioanal. Chem.*, 2020, **412**, 6177–6188.

271 Y.-F. Liu, J.-X. Chen, M.-Q. Xu and G.-C. Zhao, *Int. J. Electrochem. Sci.*, 2014, **9**, 4014–4023.

272 D. Wang, Y. Yuan, Y. Zheng, Y. Chai and R. Yuan, *Chem. Commun.*, 2016, **52**, 5943–5945.

273 Q. Hu, Y. Bao, S. Gan, Y. Zhang, D. Han and L. Niu, *Anal. Chem.*, 2020, **92**, 3470–3476.

